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Abstract 
Precision medicine refers to matching the most accurate and effective treatment to each 
individual, and has the potential to manage diseases. In cancer, however, developing 
drug candidates and finding effective combination strategies are in great demand. Here, 
we present a framework covering drug development against a specific oncoprotein, 
effective combinations of drug and natural compounds, and a physiologically-
achievable chemoprevention strategy. First, HI-B1 is synthesized and identified as a 
direct β-catenin inhibitor. A colon cancer patient-derived xenograft (PDX) model with a 
high level of β-catenin is sensitive to HI-B1. Second, a combination of aspirin with a 
ginger extract shows synergistic effect. Combining a ginger extract with aspirin 
treatment can significantly reduce the effective dose of aspirin while retaining its 
therapeutic effects in PDX mouse models. Third, multiple phytochemicals at low doses 
accumulatively inhibit one key protein to exert their chemopreventive and therapeutic 
effects. Natural ERK2 inhibitors are discovered using chemoinformatics, 
crystallography, cell biology and biochemistry. Each outcome could be used in a 
precision oncology workflow to help prevent and treat cancer efficiently. 
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Addressing the challenges of applying  
precision oncology 
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1.1 Summary 
Precision oncology is described as the matching of the most accurate and effective 
treatments with the individual cancer patient. Identification of important gene mutations, 
such as BRCA1/2 that drive carcinogenesis, helped pave the way for precision diagnosis 
in cancer. Oncoproteins and their signaling pathways have been extensively studied, 
leading to the development of target-based precision therapies against several types of 
cancers. Although many challenges exist that could hinder the success of precision 
oncology, cutting-edge tools for precision diagnosis and precision therapy will assist in 
overcoming many of these difficulties. Based on the continued rapid progression of 
genomic analysis, drug development, and clinical trial design, precision oncology will 
ultimately become the standard of care in cancer therapeutics. 
 
 
1.2 Introduction 
Improving efficacy, minimizing the adverse side effects of drugs, and overcoming 
acquired resistance to drug treatment have been major goals and emphases in cancer 
therapy. In order to attain the objectives of precision oncology, basic and clinical 
researchers have identified and clarified differences derived from genetic features 
between individuals. The existence of specific genetic differences between individuals is 
exemplified by the finding in 1932 that phenylthiocarbamide (PTC) exhibits the unusual 
property of either tasting very bitter or having no taste at all based on the individual’s 
genetics. Notably, this trait is inherited to the next generation (1-2). The “one-size-fits-all 
  3 
strategy” is no longer relevant to cancer treatment. The tailoring of distinct treatments to 
each specific individual became known as “personalized medicine” (3) and later the name 
was changed to “precision medicine” (4). Many countries have now launched 
government-driven projects focusing on precision medicine, including the Precision 
Medicine Initiative (National Institutes of Health, USA) (4), Cancer Moonshot program 
(5) (National Cancer Institute, USA) and HORIZON 2020 Work Programme for 2016 to 
2017 (EU) (6).  
The accelerating momentum of precision medicine, and especially precision 
oncology, has stemmed from the increasing amount of “-omics” information acquired 
from patients and, importantly, the successful integration of the fields of basic and 
clinical cancer research (see a detailed discussion in Appendix). Next generation 
sequencing instrumentation is capable of sequencing several genomes a day at a cost of 
about $1,000 each, making this technology an essential and straightforward part of 
translational cancer research (7). Driver-gene mutations identified from comprehensive 
genome analyses are now frequently detected in many cancer patients; and the aberrant 
gene products are currently being targeted by specific antagonists or monoclonal 
antibodies (8). Oncologists are now able to stratify subsets of cancer and make informed 
therapeutic decisions. Consequently, targeted therapy has gained credibility in reinforcing 
and/or replacing conventional cytotoxic chemotherapy. Several targeted agents are 
presently approved by the FDA and are being used clinically against several types of 
cancer. 
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Here, we categorize the work flow of precision oncology into two segments, 
precision diagnosis and precision therapy, and provide milestones and important aspects 
characterizing each segment. By reviewing targeted therapies clinically approved against 
breast cancer, lung cancer and melanoma, we reveal the current status and expose 
possible challenges in precision oncology. Two of the most effective state-of-the-art tools 
for the success of precision oncology are also described.  
 
 
1.3 Precision oncology for patients–from precision diagnosis to 
precision therapy 
In order to better understand and utilize precision oncology (i.e., precision 
medicine as it applies to cancer), analyzing the procedures step by step is crucial. 
Precision oncology comprises precision diagnosis and precision therapy. Precision 
diagnosis begins with an accurate diagnosis of each individual cancer patient and ideally 
classifies subjects into cancer patients and individuals at high risk for specific cancers (9). 
By detecting biomarkers that are associated with specific cancer types such as BRCA1/2 
mutations in breast cancer (10-11), we can diagnose the current or potential risks of each 
individual. Accumulating evidence shows that multiple biomarkers (so called 
“signature”) can help in creating more precise and evidence-based therapeutic strategies 
to modulate cancer (12-13). Establishing molecular subtypes and categorizing tumors 
into one of the subtypes enhances the accuracy of therapeutic options (14). The 
information derived from precision diagnosis reveals the precise medical measures, 
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including surgery, radiation, chemotherapy, adjuvant therapy, supplements, and/or 
vaccines, that are needed for each individual.  
Precision therapy matches the most effective treatment to the individual cancer 
patient based on the genetic profile of the specific cancer, and can be divided into two 
categories that include precision chemotherapy and precise therapeutic procedures. 
Precision chemotherapy is the use of the correct drugs prescribed that assures maximum 
benefit with minimum risk or toxicity for the patient. Therapeutic measures could include 
surgery and radiation therapy tailored to the patient’s needs.  
 
 
1.4 Precision diagnosis 
Information-based diagnosis can assist clinicians, not only in identifying tumor 
type and stage, but in revealing important genetic mutations that drive carcinogenesis. 
Advances in technology have clearly resulted in more effective therapeutic decisions. 
Final goals include optimization of clinical outcomes, avoidance of unnecessary 
therapies, minimized side effects, and overcoming or avoiding drug resistance. 
  
1.4.1 BRCA1/2 are a milestone for precision diagnosis 
The discovery of the breast cancer susceptibility genes, BRCA1/2, was traced from a 
family with a history of breast cancer, and indicated the association between genetic 
features and the early onset of the disease (10-11). In addition to other breast cancer 
susceptibility genes, the BRCA1/2 mutation test is one of the most well-established 
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models in precision oncology. It has become a guideline that aids clinicians in creating 
prevention strategies and targeted therapies. More than one million individuals have been 
tested for BRCA1/2 mutations worldwide (15). 
The landscape of mutations in the BRCA1/2 genes has been extensively studied 
and the relationship between the mutations and breast cancer risk is also well-defined. 
More than 1,800 different variants (i.e., intronic changes, insertions, deletions and 
missense mutations) have been observed in BRCA1 and 2,000 different variants have 
been reported to occur in BRCA2 (15). BRCA1/2 mutations are currently the most 
significant gene variations in breast cancer surpassing tumor protein p53 (TP53), 
phosphatase and tensin homolog (PTEN), liver kinase B1 (LKB1) and cadherin1 (CDH1) 
mutations (15-17). BRCA1/2 mutations are estimated to account for approximately 15% 
of the relative familial risk of breast cancer (15). Mutations in BRCA1 and BRCA2 
reportedly contribute equally to early-onset breast cancer (18). 
 
1.4.2 Development and improvement of genetic tests 
 Recent progress in immunohistochemistry (IHC) has helped clinicians to identify 
the presence of specific biomarkers and to categorize patients in pathology (19). 
Detection of HER2 (20) in breast cancer and PD-L1 (21) in lung cancer based on IHC 
aided the prescription of suitable drugs for the patients. However, many other techniques 
are currently available to quantify changes in gene expression, and include RT-PCR (22), 
DNA arrays (23), NanoString technology (24), comparative genomic hybridization 
arrays, and single nucleotide polymorphism analysis (25). Genetic tests have been 
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developed for diagnostic, predictive and prognostic purposes and some have been 
approved by the FDA, whereas others are still under development for breast cancer (26-
34), lung cancer (35-41) and melanoma (42-46) (Table 1.1). Although the most 
significant genes, such as BRCA1/2, can only predict or explain a portion of disease 
susceptibility, the number of genes examined in a single test has continually increased to 
improve accuracy (13). Of particular note (Table 1.1), the 70-gene signature test for 
breast cancer (MammaPrint by Agendia) (26) showed the most efficacy in a clinical trial 
(47). The study in 6,693 women with early-stage breast cancer was conducted to examine 
whether the gene signature test could reduce the use of chemotherapy. For patients who 
had high clinical risk and low genomic risk for recurrence, the difference in the 5-year 
survival rates between chemotherapy (98.8%) and no-chemotherapy (97.3%) was only 
1.5% (47). The result shows that approximately 46% of women with breast cancer who 
are at high clinical risk might not require chemotherapy and that the 70-gene signature 
could aid in treatment decisions (47). The Oncotype Dx test by Genomic Health also 
helps clinicians in selecting proper treatment options for patients with invasive breast 
cancer (31, 48). The Oncotype Dx test generates a recurrence score (0-100) by analyzing 
the expression of 21 genes (49-50). Survival rates of patients with high recurrence scores 
(31 and higher) have been improved by adjuvant chemotherapy, whereas patients with 
low recurrence scores (less than 17) are unlikely to get benefits from the chemotherapy 
(48). 
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Table 1.1 Genetic tests for breast cancer, lung cancer and melanoma 
 
Type Test name Institution FDA 
approval 
No. 
of 
genes 
Ref. 
Breast 
cancer 
MammaPrint Agendia 
Yes 
70 (26) 
Prosigna NanoString Tech. 50 (30) 
GeneSearch BLN test Veridex 2 (27) 
INFORM HER2 Dual 
ISH 
Ventana 1 (29) 
HER2 CISH pharmDx 
Kit 
Dako 1 (28) 
Oncotype Dx Genomic Health 
No 
21 (31) 
EndoPredict Sividon 
Diagnostics 
11 (32) 
Breast Cancer Index test BioTheranostics 7 (33) 
FEMTELLE Sekisui 
Diagnostics 
2 (34) 
Lung 
cancer 
Therascreen EGFR RGQ 
PCR kit 
QIAGEN 
Yes 
1 (37) 
cobas EGFR Mutation 
Test 
Roche 1 (35) 
VENTANA ALK 
(D5F3) CDx Assay 
Ventana Medical 
Systems 
1 (38) 
Vysis ALK Break Apart 
FISH Probe Kit 
Abbott Molecular 1 (36) 
Lung Cancer Mutation 
Panel  
Quest Diagnostics  
No 
34 (39) 
Lung Cancer 
Comprehensive Mutation 
and Translocation Panel 
ARUP 
Laboratories 
11 (40) 
SnaPshot Multiplex 
System 
Thermo Fisher 11 (41) 
Melanoma 
cobas 4800 BRAF V600 Roche Yes 1 (42) THxID-BRAF bioMerieux 1 (43) 
53-Immune Gene 
Network Panel 
Icahn School of 
Medicine Mount 
Sinai No 
53 (44) 
myPATH Myriad 23 (45) 
Sentosa SQ Melanoma 
Panel 
Vela Diagnostics 10 (46) 
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1.5 Precision therapy 
    Precision therapies have been applied in breast cancer, lung cancer and 
melanoma, but many challenges still need to be addressed. 
 
1.5.1 Breast cancer and targeted therapy 
 The most well-known target-based treatment against breast cancer is directed at 
the estrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2; 
Table 1.2) (51). The discovery of these two protein receptors opened a new avenue for 
targeted therapy that showed improved efficacy compared to aromatase inhibitors, which 
suppress plasma estrogen levels in postmenopausal women (52). Tamoxifen, a pro-drug 
targeting the ER, is metabolized in the liver into active metabolites that have a higher 
affinity for the ER compared to the parental tamoxifen (53). Trastuzumab is a 
monoclonal antibody targeting HER2 and is used in patients with breast cancers 
overexpressing this receptor (Table 1.2) (54-55). Trastuzumab inhibits the activity of 
HER2, which forms heterodimers with other tyrosine kinase receptors (i.e., EGFR, HER3 
and HER4) and promotes tumorigenesis (56). From a clinical trial of 469 women with 
metastatic breast cancer overexpressing HER2, combinational treatment with 
trastuzumab and standard chemotherapy attenuated disease progression compared to 
standard chemoptherapy alone (i.e., median, 4.6 vs. 7.4 months) (57). The objective 
response rate (i.e., 32 vs. 50%) and survival time (i.e., median, 20.3 vs. 25.1 months) 
were also improved by the addition of trastuzumab to the chemotherapy (57). A 
combination of pertuzumab, trastuzumab, and chemotherapy (i.e., docetaxel) improved 
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the median overall survival time (i.e., 40.8 vs. 56.5 months) compared to trastuzumab-
only plus chemotherapy (58). A conjugate drug of a HER2 monoclonal antibody and a 
cytotoxic drug, ado-trastuzumab emtansine, prolonged progression-free survival and 
overall survival with lower adverse effects compared with a combination of lapatinib and 
chemotherapy (Table 1.2) (59). 
 
 
Table 1.2 Targeted therapies in breast cancer 
Target gene Alteration Drug type Examples 
HER2/ERBB2 Amplification/mutation HER2 
inhibitor 
Trastuzumab,  
Ado-trastuzumab 
emtansine, 
Pertuzumab,   
Lapatinib 
ER 
 
 
- ER inhibitor Tamoxifen 
Amplification ER 
downregulator 
Fulvestrant 
EGFR Amplification/mutation EGFR 
inhibitor 
Gefitinib, Erlotinib, 
Afatinib, Osimertinib, 
Olmutinib, Cetuximab 
PI3-K Amplification/mutation mTOR 
inhibitor 
Rapamycin, 
Everolimus AKT1/2/3 Amplification 
PTEN Mutation/deletion 
mTOR Amplification 
KRAS Amplification/mutation BRAF, MEK 
inhibitor 
Vemurafenib, 
Trametinib BRAF Amplification/mutation 
NF1 Mutation 
CDKN1B Alteration CDK4 
inhibitor 
Palbociclib 
CCND1 Amplification 
BRCA1/2 Mutation/deletion PARP 
inhibitor 
Olaparib 
ATM Mutation 
ATR Mutation 
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1.5.2 Challenges of targeted breast cancer therapies 
 The identification of driver genes in breast cancer increases the likelihood of 
matching the correct, most effective drug to the right patient. Only a few genes, however, 
have been validated to act as driver genes. BRCA1/2, estrogen receptor alpha (ESR1), 
HER2, PI3-K/Akt/mTOR, Egfr, cyclin dependent kinase 4 (CDK4)/Rb, Ras/Raf/mitogen-
activated protein kinase kinase (MEK) are known to be critical in breast cancer therapy 
(Table 1.2) (60-61). For instance, somatic mutations of PI3-K occur in more than 10% of 
all breast cancers (61) and Akt1 and Akt3 mutations and PTEN deletion contribute to the 
activation of the PI3-K pathway (25, 62). Nevertheless, approximately 50% of the 
familial relative risk (the ratio of the risk of disease for a relative of an affected individual 
to that for the general population) of breast cancer is still unexplained (15). Couch et al. 
estimated that contributions of genes including BRCA1/2, TP53, PTEN, LKB1, CDH1, 
and known/predicted single nucleotide polymorphisms in breast cancer, and the current 
knowledge of genetic variations, only covered half of the breast cancer risk (15). 
Variants of uncertain significance (VUS) add another layer of complication in 
breast cancer treatment. VUS refers to changes in a normal gene sequence for which the 
clinical association with disease is unclear (63). Although many efforts have been made 
to evaluate and classify genetic variants, including missense, intronic, and small in-frame 
insertions and deletions (64-66), the rarity of the individual VUS makes interpretation 
difficult because of insufficient statistical power.  
 Furthermore, some breast cancer patients lack good target proteins for therapy. 
Triple-negative breast cancer (TNBC), for example, is negative for ER and progesterone 
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receptor (PgR) and lacks HER2 amplification and therefore cannot be treated with classic 
endocrine therapy or HER2-targeted therapy (67-68). The loss of HER2 expression in 
metastatic tumors compared with HER2-amplified primary breast cancers is frequently 
observed, and ER-positive/PgR-positive/HER2-amplified tumors become TNBC after 
chemotherapy (51, 69-70). Although alternative molecular targets, such as EGFR, which 
is frequently amplified and is related to poor prognosis (71-72), are being elucidated 
(Table 1.2), TNBC has only a small number of therapeutic options, and remains a 
difficult type of cancer in the field of breast cancer therapy (73). 
 
1.5.3 Lung cancer and targeted therapies 
 FDA approval of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor 
(74), accelerated target-based therapy in lung cancer patients replacing cytotoxic 
chemotherapy for first-line therapy (75-76). For patients with EGFR-activating mutations 
(exon19del or L858R), erlotinib (77-78) also performed better than conventional 
chemotherapies, such as cisplatin. EGFR-targeted therapy was combined with cytotoxic 
drugs as a combination therapy that showed improved progression-free survival (79-80). 
However, almost all patients treated with the EGFR inhibitors acquired resistance to the 
drugs due to secondary EGFR mutations such as T790M (81-82). Second-generation 
EGFR inhibitors (e.g., afatinib (83-84)) were designed to target mutant EGFR better than 
the wild-type receptor. Third-generation EGFR inhibitors, including osimertinib and 
olmutinib, irreversibly bind to EGFR T790M and have been approved for use in the U.S 
and South Korea, respectively (Table 1.3) (85-87). 
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 Crizotinib is an FDA-approved inhibitor of anaplastic lymphoma kinase (ALK), 
Ros proto-oncogene 1 (ROS1), and Met proto-oncogene (MET; Table 1.3). ALK is a cell 
surface protein that stimulates signaling pathways, such as the Ras/Raf/MEK, PI3-
K/mTOR, and Janus kinase (JAK)/signal transducer and activator of transcription 
(STAT) pathways (88), and is activated by gene translocation and fusion with other genes 
(89-94). ROS1 is an orphan receptor tyrosine kinse (RTK) activated by chromosomal 
rearrangement and fusion with other genes (95). MET, another type of RTK, is 
overexpressed/amplified or exhibits an exon 14 skip-mutation in non-small cell lung 
cancer (NSCLC) patients (96). Crizotinib has shown its superiority over standard 
chemotherapy in ALK-positive lung cancer patients (97-98) and ROS1-rearranged 
NSCLC patients (99). Lung adenocarcinoma patients harboring the MET exon 14 splice 
site mutation also responded to crizotinib (100). However, ALK mutations, such as 
R1174L, L1196M and R1275Q, conferred resistance to crizotinib and led to the 
development of second-generation ALK inhibitors. FDA has approved the use of ceritinib 
(101), which targets the L1196M gatekeeper mutation, and alectinib (102), which targets 
the R1174L, L1196M and R1275Q mutations. 
 BRAF is a signaling protein activated by various RTKs. In NSCLC, 2-4% of 
patients possess BRAF V600 mutations (96). Although BRAF inhibitors (vemurafenib 
and dabrafenib) were originally developed for the treatment of melanoma, recent clinical 
trials with the inhibitors showed potential in BRAF V600 mutant NSCLC patients (Table 
1.3). Vemurafenib resulted in tumor regression in the majority (14 of 19) of NSCLC 
patients, and the objective response rate was 42% (103). In a phase 2 trial, dabrafenib 
  14 
treatment with trametinib, a MEK inhibitor, reached 63% overall response in BRAF 
V600E-mutant NSCLC patients, who had documented tumor progression after previous 
platinum-based chemotherapy (104). 
 Immunotherapy has received substantial attention recently as a cancer therapy. 
Unlike other therapies, the goal of immunotherapy is to boost or restore the ability of 
immune cells to kill tumor cells (105). Tumor cells suppress and evade the immune 
system through interactions between the programmed cell death protein 1 (PD-1) of T-
cells and the PD ligand 1 (PD-L1) of tumor cells (106). Two monoclonal antibodies 
against PD-1 (Table 1.3), including nivolumab (107-110) and pembrolizumab (111-112), 
have received FDA approval for second-line treatment against NSCLC that express PD-
L1.  
 
Table 1.3 Targeted therapies in lung cancer 
Target 
gene 
Alteration Drug type Candidate 
EGFR Amplification EGFR inhibitor Gefitinib, Erlotinib, 
Afatinib, Osimertinib, 
Olmutinib 
ALK Translocation/mutation ALK inhibitor Crizotinib, Alectinib, 
Ceritinib 
MET Amplification MET/ROS1 inhibitor Crizotinib, 
Cabozantinib RET Amplification/mutation 
ROS1 Fusion 
PD-L1 - PD-1 inhibitor Nivolumab, 
Pembrolizumab 
HER2 Amplification HER2 inhibitor Trastuzumab, Afatinib, 
Dacomitinib 
BRAF Amplification/mutation BRAF inhibitor Vemurafenib, 
Dabrafenib 
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1.5.4 Challenges of targeted lung cancer therapies 
 The war against drug resistance is probably the most difficult challenge in lung 
cancer treatment. Clonal evolution, the accumulation of genetic and epigenetic changes 
over time in individual cells (113-114), is now believed to be the root of drug resistance 
(115-116). Biopsies that were taken after the failure of rociletinib targeting EGFR mutant 
(T790M)-expressing lung cancer (117) showed that at least a portion of the resistant 
tumor still expressed the T790-wild-type protein (116). The wild-type clones existed 
before treatment with rociletinib. Piotrowska et al. concluded that combination treatment 
using rociletinib targeting mutant EGFR T790M clones and other drugs targeting wild-
type EGFR T790 are required to further improve the drug response rate and final 
outcomes (116). However, when first-generation EGFR inhibitors (gefitinib and 
erlotinib) and third-generation EGFR inhibitors (rociletinib/CO-1686, 
osimertinib/AZD9291, olmutinib/HM61713 and WZ4002) were used in combination, a 
new mutation of C797S emerged and complicated the therapeutic options (118). Studies 
showed that if the C797S mutation was on a different allele of T790M, combination 
treatment with gefitinib and WZ4002 inhibited EGFR signaling. In contrast, if C797S and 
T790M were on the same EGFR allele, the combination of gefitinib and WZ4002 was not 
effective (118). Monitoring changes in cancer cells at the molecular level will be helpful 
in preventing and resolving drug resistance in lung cancer. 
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1.5.5 Melanoma and targeted therapies 
 BRAF in the mitogen-activated protein kinase (MAPK) pathway (Ras-Raf-MEK-
ERK) is constitutively activated by mutations in 40% of melanomas (119). The most 
common mutations are V600E and V600K, representing 73% and 19%, respectively 
(120). The growth of BRAF V600E-expressing melanoma can be inhibited directly by 
vemurafenib (121) or dabrafenib (Table 1.4) (122). Drug resistance, also called “bypass 
tracks”, is increasingly relevant as targeted therapy emerges (123). Patients with BRAF 
mutations acquired resistance due to increased expression and phosphorylation of 
platelet-derived growth factor receptor beta (PDGFβ) and N-Ras (124). The MEK 
inhibitor, trametinib, also suppresses BRAF V600E- or V600K-expressing melanomas by 
targeting the BRAF downstream MAPK pathway (Table 1.4) (125). Because drug 
monotherapies commonly result in resistance (124, 126), combination treatment with a 
BRAF inhibitor and a MEK inhibitor has been prescribed to increase the patient’s 
response rate and also lengthen their survival time (127). Especially, combination therapy 
as a first-line approach increased overall survival rates in a clinical trial (128). In patients 
with BRAF V600 mutations, a combination of cobimetinib (MEK inhibitor) and 
vemurafenib treatment showed median overall survival of 22.3 months, compared with 
17.4 months by placebo and vemurafenib treatment (128). 
 Melanoma cells express the CTLA-4 and PD-1 immune receptor proteins that are 
normally expressed in T-cells. Because each of these two proteins can inhibit activation 
of T-cells and down-regulate the immune response, the abnormal expression of CTLA-4 
and PD-1 in tumor cells is suggested as a molecular mechanism of immune evasion in 
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tumors (129). Ipilimumab, a CTLA-4 monoclonal antibody, was approved by the FDA 
for treatment of patients with metastatic melanoma (Table 1.4) (130-131). The PD-1 
monoclonal antibodies, nivolumab (132-134) and pembrolizumab (135), were also 
effective against metastatic melanoma (Table 1.4). Ipilimumab and nivolumab are also 
used in combination to treat melanoma (136). 
 
1.5.6 Challenges of targeted melanoma therapies 
 Similar to other types of cancer, one of the greatest challenges in melanoma 
treatment is the relapse and development of resistant disease after therapy. Recently, even 
patients who have undergone immunotherapy were shown to acquire resistance to PD-1 
blockade in melanoma (137). Zaretsky et al. reported a delayed relapse of patients who 
had had initial tumor regression induced by continuous pembrolizumab treatment. The 
analyses of biopsies showed that JAK1/2 truncating mutations resulted in loss of PD-L1 
expression and changed the molecular profile of the melanoma (137-138). Overall, 
although immunotherapy has become a promising and unique strategy for cancer 
treatment, an integrative strategy should be prepared to prevent drug resistance. 
 
Table 1.4 Targeted therapies in melanoma 
Target 
gene 
Alteration Drug type Candidate 
BRAF Amplification/mutation BRAF inhibitor Vemurafenib, Dabrafenib 
MEK Amplification/mutation MEK inhibitor Trametinib, Cobimetinib 
CTLA-4 Amplification CTLA-4 
inhibitor 
Ipilimumab 
PD-1 - PD-1 inhibitor Nivolumab, Pembrolizumab 
  18 
1.6 Tools for precision oncology 
 The demand for new diagnostic and treatment tools has been driven by precision 
oncology. In particular, the use of liquid biopsies and patient-derived xenograft (PDX) 
models has received considerable attention from researchers and clinicians. For precision 
diagnosis, having new diagnostic platforms like liquid biopsies is crucial because this 
type of assay can gather information from patients in a manner that is minimally-
invasive. For precision therapy, testing drugs in a paradigm like the PDX model is 
beneficial because this model can be used to represent tumors of patients before drugs are 
subscribed.  
 
1.6.1 Liquid biopsies 
 A biopsy is an examination of tissue obtained from a living body to discover the 
presence, cause, or extent of a disease. Although biopsies have become more important as 
the field of precision oncology continues to expand, sampling some types of tumors is 
still difficult and can result in diagnostic errors. To address this problem, biofluid 
samples, including serum, plasma, saliva, urine and cerebrospinal fluid, are now being 
used to screen for tumors, characterize molecular features, and analyze tumor types (139-
142). Liquid biopsies can provide clear information regarding the genetic makeup of each 
tumor. Because liquid biopsies are relatively non-invasive, clinicians can repeat sampling 
and monitor disease progression over time without performing solid-tissue biopsies. 
Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) are promising components of 
liquid biopsies.  
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 CTCs are cancer cells that are shed into the vascular system from the primary 
tumor and are circulating around the body in the blood (143). CTCs have been detected in 
patients with metastatic tumors at an average concentration of 1-10 cells/ml, but are 
extremely rare in individuals without tumors or with non-malignant tumors (139, 144-
145). Circulating non-tumor epithelial cells in the blood of patients undergoing surgery 
and the difficulty in identifying markers of CTCs pose challenges to this technology. 
However, because dynamic changes occur in surface markers of CTCs, analysis of 
DNA/RNA from CTCs can enable clinicians to predict tumor progression and drug 
susceptibility of the patient (142, 146). A clinical trial with CTCs showed its promise as a 
prognostic marker and limitation as an indicator of changing chemotherapy (147). The 
trial divided patients with metastatic breast cancer into four groups. Patients whose CTC 
number was not increased at baseline remained on initial therapy (arm A), and patients 
whose CTC numbers had been increased, but later decreased after 21 days of therapy, 
also remained on the initial therapy (arm B). Patients whose CTC numbers were 
consistently increased were randomly assigned to maintain initial therapy (arm C1) or 
changed to an alternative therapy (arm C2). Overall survival rates between arms A, B, 
and C (sum of C1 and C2) showed significant differences between groups (i.e., 35 vs. 23 
vs. 13 months, respectively). However, no difference was observed between overall 
survival of arm C1 and C2. This result indicates that CTC is a strong prognostic marker 
of overall survival in patients with metastatic breast cancer, although changing 
chemotherapy option based on CTC does not prolong the overall survival rate (147). In 
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summary, monitoring the efficacy of adjuvant therapies is feasible with CTC-based liquid 
biopsies, and analyses of CTCs will be one of the key players in precision diagnosis. 
 cfDNA refers to tumor DNA released from primary cancers into the biofluids of 
cancer patients (142). The majority of cfDNA is derived from cells that have undergone 
apoptosis or necrosis and then release fragments of DNA of approximately 150-180 bp in 
length (140, 142). Similar to acquiring CTC, tumor cell-derived cfDNA is difficult to 
obtain because of the extensive amount of cfDNA that is also released from non-
malignant cells (148). Nevertheless, cfDNA could provide a better diagnostic tool than 
CTCs from the same patient to detect mutations (149). Because cfDNA could be used to 
monitor clonal evolution and emergence of drug resistance (150), this type of analysis 
might assist clinicians in making tailored therapeutic decisions for cancer patients in the 
future. 
 
1.6.2 Patient-derived xenograft (PDX) models 
 The PDX model uses actual patient tumor fragments that have been sectioned 
from the cancer patient and implanted into immunodeficient mice (151). By treating mice 
harboring the PDX tumor fragment, the efficacy of a drug can be predicted before being 
subscribed to the actual patient. Thus PDX is a platform that provides evidence-based 
guidelines in choosing the correct and most effective drug to prescribe to a patient. For 
preclinical drug development, the PDX model overcomes the important limitation of 
using conventional cancer cell lines, which have developed characteristics that do not 
accurately reflect the actual cancer patient tumor. Conventional cell line-based xenografts 
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lack the broad diversity and heterogeneity of cancer (152). In contrast, the PDX model 
preserves the heterogeneity and microenvironment of the original tumor after being 
passaged in mice (151-152). In 1985 the PDX model was confirmed to have good 
predictive value in showing that drug responses from PDX models corresponded very 
well with the response from patients (153). The tumor heterogeneity of the PDX was 
shown to be well preserved in patient-derived tumor cells (PDTC) (154). These results 
support the potential of the PDTC-PDX pipeline for drug development. Although the lack 
of functional immune reactions in this model is a limitation, humanized mice that mimic 
the human immune system and resultant microenvironment allow researchers to better 
understand translational oncology (155). Overall, this clinically relevant mouse model 
should be beneficial in drug development and precision therapy for cancer patients. 
 Establishing PDX models worldwide reflects the high expectations of translating 
preclinical research to the clinic. Novartis, a large pharmaceutical company 
(Switzerland), has established about 1,000 PDX models expressing a diverse pool of 
driver mutations in cancer (156). EurOPDX, a European consortium for PDX, has 
established more than 1,500 subcutaneous and orthotopic PDX models (157) and the 
Jackson Laboratory (ME, USA) has created about 550 PDX models (157). The US-China 
(Henan) Hormel Cancer Institute (Zhengzhou, China) has established unique PDX 
models that include Wilms’ tumor and esophageal cancer models. Dana-Farber Cancer 
Institute (MA, USA) established a Public Repository of Xenografts (PRoXe), which 
includes PDXs of leukemia and lymphoma (158). Of particular note, EurOPDX launched 
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cBioPortal where information on models and their molecular annotation have been 
opened to the public to provide a platform of PDX studies (159). 
 
 
1.7 Limitations and prospects of precision oncology 
 Despite the growing enthusiasm and enormous investment in precision oncology, 
empirical evidence and verification is still critically needed showing that precision 
therapy is significantly better than conventional treatments (160-161). Results from one 
of the first clinical trials based on precision oncology were not promising (162). In this 
trial, the genomic information of patients was analyzed and patients who had targetable 
driver mutations were subjected to precision therapy. Unfortunately, the use of 
molecular-targeted drugs did not result in improved progression-free survival compared 
to treatments based on the clinicians’ choice (i.e., randomized trial). Another study that 
enrolled patients with different types of tumors, including colon, thyroid and ovarian 
cancer expressing the BRAF V600 mutation, showed similar results (103). In this study, 
vemurafenib, an FDA-approved drug against melanoma, was only effective on some of 
the non-melanoma patients. These results suggest that prescription of drugs against a 
certain type of cancer does not guarantee success in treatment of other types of cancers 
although they harbor the same mutation/alteration on the target protein. 
 Several factors could have led to the lack of success of the current precision 
oncology-based trials (163). One factor could be the lack of specific molecular-targeted 
drugs. Drugs are not yet available for many drivers in carcinogenesis at least partly due to 
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the tremendous cost in money and time. Furthermore, many drugs are so toxic that 
clinicians are forced to reduce the dose, which results in only a partial inhibition of the 
targeted pathway giving the tumor the opportunity to develop resistance to the drugs. 
Other factors include tumor heterogeneity and constant evolution (115, 164). In addition, 
the genomic signature from one part of the tumor measured at a certain time point likely 
does not represent other parts or different time points of tumor development. These 
features pose a huge hurdle to precision oncology. 
 To address tumor heterogeneity and evolution, the National Cancer Institute 
recently revealed a new trial design of genomically-informed precision therapy referred 
to as the NCI-MATCH (Molecular Analysis for Therapy Choice) Trial (165-166). NCI-
MATCH aims to identify ‘actionable mutations’ and test whether a drug or drug 
combinations are active against specific molecular abnormalities (166). The multi-arm 
phase 2 trial initially aimed to screen 3,000 patients and enroll 1,000 adults with 
advanced solid tumors for which standard therapy has not yet been developed. The initial 
trial with 10 treatment arms has completed accrual and patient recruitment was closed in 
November 2015 for planned interim analysis. Based on the low number of actionable 
mutations and the enrollment number exceeding expectations from the interim analysis, 
the trial reopened on May 31, 2016, extending treatment arms to 24 and aiming to screen 
6,000 patients (167). Genetic variants of the patients will be analyzed for 143 genes and 
the patients assigned to one of several different treatment groups (165). The hope is that 
this new design will increase the flexibility of clinical decisions and improve the overall 
outcome of the patients. 
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 One of the most promising and successful examples of precision oncology is the 
treatment of chronic myeloid leukemia (CML) with imatinib (168). The high proportion 
of the clonal BCR–ABL translocation in CML enabled almost all CML patients to benefit 
from imatinib (169). Likewise, finding concurrent driver mutations or clonal markers will 
benefit a large group of people. The hope is that predicting/monitoring changes in cells 
and dividing patients with subgroups before or at the point of cancer relapse will improve 
clinical outcomes.  
 Pan-cancer precision diagnosis and therapy are emerging. For instance, 
pembrolizumab, a PD-1 inhibitor, is approved by the FDA for treatment of metastatic 
melanoma (170), metastatic NSCLC (171), Hodgkin’s lymphoma (172), and metastatic 
head and neck squamous cell carcinomas (173). Although the proportion of patients who 
are eligible for the treatment is lower than that of imatinib-CML cases, this target-based 
approach provided a better treatment option compared to adjuvant chemotherapy. 
Furthermore, RTK inhibitors also aim to cover patients across various cancer types. One 
of the newest approaches is a fibroblast growth factor receptor (FGFR) inhibitor that 
directly targets its genetic alterations. BGJ398, a FGFR1-3 inhibitor, was tested in 
patients with advanced solid tumors including lung, breast, bladder, colon and liver (174). 
The phase 1 trial showed that BGJ398 exhibits anti-tumor activity against FGFR1-
amplified NSCLC and FGFR3-mutant bladder cancer (174). For precision diagnosis, 
eligible patients for targeted therapies will be screened and for precision therapy, the 
targeted drug(s) will be administered at a correct dose to benefit each individual. 
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 The advances in lipidomics, proteomics and metabolomics will aid in the 
implementation of precision oncology. In the field of lipidomics, arachidonic acid is a 
signaling precursor that has attracted interest for anti-cancer therapy (175-176). A recent 
study of lipidomic profiling showed that lung tumors possess higher levels of arachidonic 
acid-containing phospholipids and phosphatidylinositols compared to normal tissue 
(176). Myc inactivation caused a significant decrease in arachidonic acid and its lipid 
metabolites (176). These results suggest that arachinonic acid and its metabolites can 
serve as biomarkers in precision diagnosis. In the field of proteomics, cryo-electron 
microscopy (cryo-EM) has received considerable attention as a tool for “visual 
proteomics” (168, 177). For example, the structure of the ATP-binding cassette subfamily 
G2 (ABCG2), a human multidrug transporter, revealed that two cholesterol molecules are 
bound to a hydrophobic pocket between the transmembrane domains (178). The cryo-EM 
structure provides structural insights of cholesterol recognition and pharmacokinetics of 
ABCG2 in precision therapy. In the field of metabolomics, gut microbiota possess a large 
repertoire of metabolizing xenobiotics, small molecules that are foreign to the human 
body (179). For example, irinotecan becomes SN-38, an active topoisomerase inhibitor in 
the body (180). SN-38 is glucuronidated by host liver enzymes and loses its activity (SN-
38G). However, bacterial β-glucuronidase hydrolyzes and reactivates SN-38G in the 
large intestine causing intestinal damage and diarrhea (180). Accumulative knowledge of 
microbiota in each patient could enhance the efficacy of precision therapy and lower 
adverse side effects. 
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 To summarize, precision oncology has emerged to improve efficacy, minimize 
side effects of drugs and avoid drug resistance in cancer therapy. Precision oncology is 
categorized into two segments, precision diagnosis and precision therapy. In precision 
diagnosis, mutations of important genes such as BRCA1/2 have led clinicians to tailor 
treatment options to individuals. Improvement on genetic tests facilitated molecular 
target-based precision therapy. In breast, lung and melanoma, drugs that inhibit important 
target proteins prolonged progression-free survival and overall survival of the patients 
compared to genotoxic chemotherapy. Although difficulties due to clonal evolution and 
cancer heterogeneity still exist, state-of-the-art tools such as liquid biopsies and PDX 
models will enhance the efficacy of precision diagnosis and precision therapy, 
respectively. Supported by government-driven projects worldwide, precision oncology 
will be the standard pipeline of cancer therapy. 
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Chapter 2: 
A small molecule inhibitor of the β-catenin-TCF4 
interaction suppresses colorectal cancer growth  
in vitro and in vivo 
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2.1 Summary 
Colorectal cancer is associated with aberrant activation of the Wnt pathway. β-
Catenin plays essential roles in the Wnt pathway by interacting with T-cell factor 4 
(TCF4) to transcribe oncogenes. We synthesized a small molecule, referred to as HI-B1, 
and evaluated signaling changes and biological consequences induced by the compound. 
HI-B1 inhibited β-catenin/TCF4 luciferase activity and preferentially caused apoptosis of 
cancer cells in which the survival is dependent on β-catenin. The formation of the β-
catenin/TCF4 complex was disrupted by HI-B1 due to the direct interaction of HI-B1 
with β-catenin. Colon cancer patient-derived xenograft (PDX) studies showed that a 
tumor with higher levels of β-catenin expression was more sensitive to HI-B1 treatment 
compared to a tumor with lower expression levels of β-catenin. The different sensitivities 
of PDX tumors to HI-B1 were dependent on the β-catenin expression level and 
potentially could be further exploited for biomarker development and therapeutic 
applications against colon cancer. 
 
 
2.2 Introduction 
Colon cancer is the third most common cancer diagnosed in both men and women 
in the United State (181). Although the incidence rate of colon cancer is decreasing due 
to introduction of colonoscopy and removal of precancerous lesions, incidence and death 
rates are still increasing among people younger than 50 years old (181). Chemotherapy of 
colon cancer has been heavily dependent on 5-fluorouracil (5-FU), a genotoxic drug that 
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blocks DNA synthesis and replication. Since target-based intervention was introduced in 
cancer therapy, epidermal growth factor receptor (EGFR) inhibitors combined with 5-
FU-based treatment have increased the overall survival rate of colorectal cancer patients 
with K-ras wild-type gene expression (182-183). However, the elucidation of additional 
important targets and the development of specific inhibitors are still challenging goals. 
β-catenin is a central component of the Wnt signaling pathway, and aberrant 
expression or prolonged activation of β-catenin is frequently associated with various 
diseases, including cancer (184-186). The role of β-catenin and Wnt signaling in 
carcinogenesis has been studied extensively in cancer, especially in colorectal cancer. 
The expression level and the activity of β-catenin is tightly regulated by its upstream 
regulator, the destruction complex, which includes the tumor suppressor adenomatous 
polyposis coli (APC), glycogen synthase kinase 3β (GSK3β), casein kinase 1α (CK1α) 
and the scaffold protein AXIN (187). When translocated from the cytosol to the nucleus, 
β-catenin binds with T-cell factor 4 (TCF4) to transcribe target genes such as axin2 (188), 
cyclin D1 (189) and c-myc (190).  
The importance of the Wnt pathway in tumorigenesis has made it a promising 
target for drug development (186). Over the past decade, the down-regulation of Wnt 
signaling in cancer cells was achieved by small molecules (191). Compounds that target 
upstream of β-catenin include tankyrase inhibitors IWR-1 (192) and XAV939 (193) and 
casein kinase 1α activator pyrvinium (194). These inhibitors facilitate β-catenin 
degradation by enhancing the activity of the β-catenin destruction complex. Direct 
inhibition of β-catenin by PKF115-584 (195) and CGP049090 (196) reduces target gene 
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expression without affecting the protein expression level of β-catenin. Methyl 3-([(4-
methylphenyl)sulfonyl]amino)benzoate (MSAB) was recently reported to target β-catenin 
and induce ubiquitination (197). MSAB selectively killed Wnt-dependent cancer cells 
(197). Despite these efforts, the effectiveness of Wnt/β-catenin inhibitors in clinical trials 
is yet to be proven, and strategies to identify patients who will respond to the inhibitors 
are still largely elusive (186). 
The patient-derived xenograft (PDX) model comprises a surgically dissected 
clinical tumor sample that is implanted into immuno-deficient mice (159). Unlike 
established cell lines that are cultured in vitro for many passages, the PDX tumor is 
believed to recapitulate tumor heterogeneity and, thus, better reflects the features of the 
original human cancer (151-152). In particular, the PDX model has become a valuable 
tool to test small molecules with anti-cancer activities in drug discovery and biomarker 
development (152, 198). Although the PDX model can be perceived as time-consuming 
to establish and might be highly variable, drug responses obtained from PDX mice are 
highly consistent with responses observed in human patients (159). For example, the 
overall response rates of EGFR antibodies in PDX colorectal cancer studies were similar 
to those found in the clinic (199-200). A comparative analysis of EGFR antibody 
sensitivities in PDX models (201) and patient (202) populations in different studies 
revealed that the response rate in PDX can reflect the clinical outcome (159).  
Herein, we synthesized a small molecule, referred to as HI-B1, and report that the 
small molecule shows an inhibitory effect against β-catenin/TCF4 luciferase activity in 
colon cancer cells. HI-B1 preferentially causes apoptosis of cancer cells in which the 
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survival is dependent on β-catenin. The inhibition of the β-catenin/TCF4 pathway by HI-
B1 resulted in apoptosis and binding assays show that β-catenin is a direct target protein 
of HI-B1. HI-B1 disrupts the interaction between β-catenin and TCF4 in vitro and ex 
vivo. A PDX colon cancer study showed that HI-B1 inhibits the growth of tumors with a 
high expression level of β-catenin, but was not effective against tumors with a low level 
of β-catenin. We anticipate that these preclinical results will provide the groundwork for 
translational research of β-catenin inhibitors and development of biomarkers to match 
patients with inhibitors in era of precision oncology. 
 
 
2.3 Results 
2.3.1 HI-B1 preferentially attenuates growth and induces apoptosis of 
cancer cells in which β-catenin is essential for survival. 
HI-B1 was synthesized (Figure 2.1a), and subjected to a β-catenin/TCF4 
luciferase assay to test its efficacy against the Wnt/β-catenin signaling pathway. HI-B1 
inhibited β-catenin/TCF4 luciferase activity in a dose-dependent manner in two different 
colon cancer cell lines (Figure 2.1b).  Because the inhibition of Wnt/β-catenin activity 
can reportedly kill cancer cells (192, 195-196, 203-207), the effect of HI-B1 on cell 
growth and apoptosis was investigated. HI-B1 treatment suppressed growth of several 
types of colon cancer cells (DLD1, CACO2 and HCT116), but did not affect the H838 
lung cancer cell line (Figure 2.1c). Because H838 was reported as a cell line that 
expresses little or no β-catenin (208), the specificity of HI-B1 on the β-catenin pathway 
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was further examined. By using short hairpin RNA that target β-catenin, we were able to 
find cell lines in which the survival is dependent on β-catenin. Knockdown of β-catenin 
resulted in apoptosis in DLD1, CACO2 and HCT116 cells, whereas H838 and CCD-
18Co cells were only marginally affected by the knockdown (Figure 2.1d). HI-B1 
treatment also preferentially resulted in more apoptosis in DLD1, CACO2 and HCT116 
compared to H838 and CCD-18Co cells (Figure 2.1e).  
 
 
 
 
 
Figure 2.1a Chemical structure of HI-B1. 
 
 
  33 
 
Figure 2.1b The effect of HI-B1 on β-catenin/TCF4 luciferase activity. DLD1 (upper 
panel) and CACO2 (lower panel) cells were transfected with TOPFlash, which contains 
TCF4 binding sequences, or FOPFlash (as a negative control) and then treated with 
different doses of HI-B1 for 24 hr. Firefly luciferase activity was normalized with Renilla 
luciferase activity. 
  
  34 
 
 
 
 
 
Figure 2.1c The effect of HI-B1 on cell viability. Cells were treated with HI-B1 at 
different doses for 48hr and then viability was assessed by MTS assay. 
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Figure 2.1d The effect of β-catenin knock-down on apoptosis in DLD1, CACO2, 
HCT116, H838 and CCD-18Co cell lines. Cells were incubated for 48 hr after the shRNA 
infection and antibiotic selection. Apoptosis was measured by annexin V/propidium 
iodide staining and flow cytometry. 
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Figure 2.1e The effect of HI-B1 on apoptosis in DLD1, CACO2, HCT116, H838 and 
CCD-18Co cell lines. Cells with β-catenin-dependent growth (DLD1, CACO2 and 
HCT116) and β-catenin independent growth (H838 and CCD-18Co) were treated with 
HI-B1. Apoptosis was measured after 48 hr of treatment with flow cytometry. All values 
of graphs present mean ± standard deviation (SD) (in triplicate). Significant differences 
were calculated by one-way ANOVA compared with DMSO-treated group or sh-mock 
group (*P < 0.05, **P < 0.01, ***P < 0.001). 
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2.3.2 HI-B1 inhibits anchorage-independent growth of colon cancer cells 
by reducing β-catenin target gene expression. 
Because β-catenin is a primary driver in colon cell transformation (209), the effect 
of HI-B1 was examined using soft agar, a laboratory measurement of cell transformation 
and anchorage-independent growth of cancer cells. Results indicated that HI-B1 
treatment significantly inhibited anchorage-independent growth of DLD1 and HT-29 
colon cancer cells (Figure 2.2a). The growth of CACO2, another colon cancer cell line, 
was also suppressed by HI-B1 in a 7-day proliferation assay (Figure 2.2b).  To further 
confirm the effect of HI-B1 on the β-catenin pathway, an H-ras/β-catenin-induced foci 
formation assay was conducted. According to previous studies (210-211), constitutively 
active Ras facilitates nuclear translocation of β-catenin to induce cell transformation. In 
agreement with these results (211), foci formation of NIH3T3 cells was substantially 
induced by co-transfection of H-ras and β-catenin, but not by single gene transfection 
(Figure 2.2c). Notably, HI-B1 attenuated H-ras/β-catenin-induced foci formation. These 
results reveal that HI-B1 inhibits anchorage-independent growth and foci formation 
where β-catenin plays an important role. 
We next focused on the details of the Wnt/β-catenin signaling pathway affected 
by HI-B1. Quantitative real-time PCR results showed that HI-B1 treatment decreased 
mRNA expression of cyclin D1 and axin2 in DLD1 and CACO2 cell lines (Figure 2.2d). 
HI-B1 also down-regulated cyclin D1 and c-Myc protein levels (Figure 2.2e). Of 
particular note, the β-catenin protein level was not changed by HI-B1 either at the protein 
or mRNA level. This suggests that HI-B1 could inhibit the nuclear translocation of β-
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catenin (212) or directly bind to β-catenin and suppress its activity (186). Cytosolic and 
nuclear fractions were treated or not treated with HI-B1 and results showed that nuclear 
translocation of β-catenin was not altered by the compound, which suggested a direct-
binding mechanism of action (Figure 2.2f).  
 
 
 
Figure 2.2a The effect of HI-B1 on anchorage-independent growth of DLD1 and HT29 
colon cancer cell lines. Cells were seeded into 0.3%-agar-containing medium with 
various concentrations of HI-B1 and the numbers of colonies was counted at Day 7. 
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Figure 2.2b The inhibitory effect of HI-B1 on CACO2 cell growth. Cells were seeded on 
6-well plates with various concentrations of HI-B1 and then stained with crystal violet 
solution at Day 7. 
 
 
 
Figure 2.2c The inhibitory effect of HI-B1 on β-catenin/H-ras-induced cell 
transformation of NIH-3T3. Foci formation was induced by co-transfection of β-catenin 
and H-ras (H12V) in NIH3T3. After transfection, cells were treated with HI-B1 and 
stained with crystal violet solution (Day 14). The medium was changed every other day. 
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Figure 2.2d The effect of HI-B1 on mRNA expression of β-catenin target genes in DLD1 
and CACO2 cells. After 24 hr of HI-B1 treatment, mRNA was harvested from the cells 
and relative amount was measured by qRT-PCR. All values of graphs present mean ± SD 
(in triplicate). Significant differences were calculated by one-way ANOVA compared 
with DMSO-treated group (*P < 0.05, **P < 0.01, ***P < 0.001).  
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Figure 2.2e The effect of HI-B1 on cyclin D1 and c-Myc protein expression. After 24 hr 
of HI-B1 treatment, protein was harvested from the cells and relative amount was 
measured by western blotting.  
 
 
Figure 2.2f The effect of HI-B1 on β-catenin translocation in DLD1 cell. The cytosol and 
the nucleus portions of the cells were fractionated at 24hr of HI-B1 treatment. Lamin B 
and α-tubulin were used as a cytosol and a nucleus marker, respectively. 
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2.3.3 HI-B1 directly binds with β-catenin, but not TCF4, to disrupt the 
β-catenin/TCF4 interaction. 
To determine whether HI-B1 binds to β-catenin, HI-B1 was conjugated to 
Sepharose 4B-beads and incubated with cell lysates. β-Catenin was detected by Western 
blot and results showed that HI-B1 directly binds with β-catenin (Figure 2.3a). Notably, 
TCF4, which is a binding partner of β-catenin, with which it forms a complex and 
induces gene transcription, was not bound to HI-B1. The interaction between β-catenin 
and TCF4 has been implicated as a core element of the Wnt pathway in colorectal cancer 
cell growth (213). The binding of HI-B1 with β-catenin disrupted the interaction between 
β-catenin and TCF4 in vitro (Figure 2.3b). His-tagged β-catenin and GST-tagged TCF4 
were incubated with or without HI-B1 and His-β-catenin was pulled down with nickel 
beads. The amount of TCF4 co-immunoprecipitated with β-catenin was decreased in HI-
B1 treated groups. The effect of HI-B1 against β-catenin/TCF4 complex formation was 
also confirmed in DLD1 and CACO2 cell lines (Figure 2.3c). These results demonstrate 
that HI-B1 directly binds with β-catenin and disrupts the β-catenin/TCF4 interaction. 
We next conducted in silico docking, to predict the important binding residues of 
HI-B1. A nitrogen atom was found to be responsible for a hydrogen bond with β-catenin 
(Figure 2.3d). HI-B1-NC, a derivative of HI-B1 in which the nitrogen atom (N) is 
substituted with a carbon atom (C), was synthesized and its biological activities were 
compared with HI-B1. The N to C substitution completely attenuated the effect of HI-B1 
against DLD1 colon cancer cell growth (Figure 2.3e). The inhibitory effect on β-
catenin/TCF4 luciferase activity was also eliminated by the substitution (Figure 2.3f). 
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Overall, the nitrogen atom of HI-B1was found to be important for its direct binding with 
β-catenin. 
 
 
 
Figure 2.3a Binding assay of HI-B1 on β-catenin ex vivo. HI-B1 was conjugated with 
Sepharose 4B beads and incubated with cell lysates. Protein co-immunoprecipitated with 
the beads was analyzed by western blotting. 
  44 
 
Figure 2.3b The effect of HI-B1 on β-catenin/TCF4 interaction in vitro. HI-B1 disrupts 
the formation of the β-catenin/TCF4 complex in vitro. His-tagged β-catenin (126-686) 
was immunoprecipitated with nickel beads and the amount of TCF4 was detected by 
western blotting. 
 
 
 
Figure 2.3c The effect of HI-B1 on β-catenin/TCF4 interaction in DLD1 and CACO2 
cell lines. Cell lysates were harvested after 24hr of HI-B1 treatment. β-Catenin was 
immunoprecipitated and binding proteins was detected by western blotting. 
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Figure 2.3d Molecular docking predicts the interaction of HI-B1 and β-catenin. A 
nitrogen atom of HI-B1 forms a hydrogen bond with β-catenin (upper panel) from Extra 
precision (XP) docking in silico (lower panel).  
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Figure 2.3e The effect of HI-B1 and HI-B1-NC on cell viability. HI-B1 and HI-B1-NC 
(a nitrogen atom was substituted with a carbon) were treated to DLD1 cells (n=3). 
Proliferation was measured by MTS assay at 48 hr. 
 
 
Figure 2.3f The effect of HI-B1 and HI-B1-NC on luciferase activity. β-catenin/TCF4 
luciferase activity was measured by luminometer at 24 hr. Significant difference with 
DMSO-treated group by One-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001).
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2.3.4 HI-B1 suppresses polyp formations in APCmin model and decreases 
the growth of patient-derived xenograft (PDX) tumors with a high 
expression level of β-catenin. 
To verify the efficacy of HI-B1 in vivo, a PDX colon cancer model was utilized. 
Tumor fragments were from two different patients (JG5 and JG14) and 
immunohistochemistry analysis of the two PDX tumors indicated a difference in β-
catenin expression. JG5 had a high level of β-catenin expression compared to JG14 
(Figure 2.4a). The effect of HI-B1 was examined on each of the two colon cancer PDX 
models to determine whether the expression level of β-catenin could be a predictive 
marker for sensitivity to a β-catenin inhibitor. Interestingly, HI-B1 treatment reduced the 
weight and volume of the JG5 PDX tumor, but had no effect on the JG14 PDX tumor 
(Figure 2.4b and c). Although the efficacy of HI-B1 against only two PDX tumors with 
differential levels of β-catenin expression, this suggests that tumors with higher levels of 
β-catenin might be more sensitive to β-catenin inhibitor treatment. The decrease in c-myc 
expression by HI-B1 was confirmed by immunohistochemistry (Figure 2.4d). Further 
studies testing HI-B1 in more PDX tumors will be needed. 
To further confirm the in vivo efficacy of HI-B1, the APCMin mouse model was 
utilized. This mouse model exhibits aberrant activation of β-catenin, and HI-B1 treatment 
reduced the number of polyps (Figure 2.4e). In addition, the mRNA expression levels of 
c-myc and cyclin D1 (Figure 2.4f and g) were also decreased. Overall, these results 
indicate that HI-B1 inhibits β-catenin-driven tumorigenesis in vivo. 
  48 
 
Figure 2.4a β-Catenin expression levels in colon cancer PDX. Integrated optical density 
(IOD) of immunohistochemistry was quantified using Image-Pro Plus software. 
 
 
Figure 2.4b HI-B1 inhibits JG5 tumor growth. HI-B1 was administered per os (p.o) 
(orally) three times a week at a dose of 50 mg/kg (n = 8/group). Tumor size was 
measured three times a week and the weight was measured at the end of experiments.  
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Figure 2.4c HI-B1does not affect JG14 tumor growth. 
 
Figure 2.4d The effect of HI-B1 on c-Myc expression of JG5 PDX tumor. In the JG5 
PDX tumor, c-Myc Expression level change by HI-B1 treatment was measured by IHC.  
 
 
  
Figure 2.4e HI-B1 reduced polyp formation driven by aberrant activation of β-catenin in 
APCmin mouse model. The indicated doses of HI-B1 were administered p.o. for 10 weeks, 
and mice were sacrificed for analysis of intestinal carcinogenesis (n = 6/group). 
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Figure 2.4f The effect of HI-B1 on c-myc mRNA expression in APCmin mouse model. 
Small intestine tissue was prepared from the same position of ileum from mice, and then 
mRNA expression levels of c-myc was quantified by qRT-PCR. 
 
 
Figure 2.4g The effect of HI-B1 on cyclin D1 mRNA expression in APCmin mouse model. 
Small intestine tissue was prepared from the same position of ileum from mice, and then 
mRNA expression levels of cyclin D1 was quantified by qRT-PCR. (One-way ANOVA; 
*P < 0.05, **P < 0.01, significant difference compared to the vehicle group.) 
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2.4 Discussion 
Most cases of sporadic colon cancer are caused by genetic mutations of several 
Wnt pathway proteins, including APC, axin and β-catenin, resulting in stabilization of β-
catenin and the formation of the β-catenin/TCF4 complex (185, 214). Although a number 
of inhibitors against the Wnt pathway and β-catenin have already been identified, the 
development of β-catenin inhibitors with specificity on the β-catenin pathway still has 
value. In this study, the identification of HI-B1 as an inhibitor of β-catenin/TCF4 
luciferase activity (Figure 2.1b) provided an opportunity to develop a drug candidate 
against the β-catenin pathway. The molecular mechanism of HI-B1 was investigated and 
revealed its direct binding to β-catenin and disruption of the β-catenin/TCF4 interaction 
(Figure 2.3b and c). Based on the promising in vitro experimental results, we sought to 
establish its efficacy in vivo. A PDX tumor expressing high levels of β-catenin was more 
sensitive to β-catenin inhibitor treatment compared to another tumor expressing lower 
levels of β-catenin (Figure 2.4b and c). Notably, we showed that a β-catenin inhibitor 
could attenuate the growth of a colon cancer patient-derived tumor, and that sensitivity to 
the inhibitor might be dependent on the expression level of β-catenin.  
Our study provides a rationale for detecting β-catenin levels when Wnt/β-catenin 
inhibitors are tested to colon cancer patients. The significant difference between β-catenin 
expression levels of colon cancer patients (Figure 2.4a) was rather unexpected, regarding 
the well-known importance of β-catenin in colorectal cancer (186). As HER2 (human 
epidermal growth factor receptor 2)-targeted drugs, such as lapatinib and trastuzumab, 
are recommended only to HER2-positive breast cancer patients (215), HI-B1 was only 
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effective in PDX where β-catenin is highly expressed (Figure 2.4b and c). These results 
suggest that β-catenin expression level might be correlated with the efficacy of Wnt/β-
catenin inhibitors against colon cancer. Such information could be further exploited for 
biomarker development and therapeutic applications against colon cancer, especially in 
ongoing clinical trial of Wnt pathway inhibitors. 
 
 
2.5 Materials and Methods 
2.5.1 Reagents  
All antibodies were commercially available, including β-catenin, β-actin, cyclin 
D1, α-tubulin and GST from Santa Cruz Biotechnology (Santa Cruz, CA), c-Myc and 
TCF4 from Cell Signaling Technology (Beverly, MA), lamin B from Calbiochem (San 
Diego, CA). The luciferase assay substrate and the Cell Titer 96 Aqueous One Solution 
Reagent [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 
2H-tetrazolium, inner salt (MTS)] kit were from Promega (Madison, WI). 
 
2.5.2 Synthesis of 4-(5-fluoro-1H-benzo[d]imidazol-2-yl)-N,N-
dimethylaniline (HI-B1) 
To a solution of 4-(Dimethylamino)benzaldehyde (2.98 g, 20 mmol) in ethanol 
(40 mL), Sodium dithionite (3.48 g, 20 mmol) in water (20 mL) was added. The resulting 
mixture was stirred at room temperature for 20 min and then 4-Fluoro-1,2-
phenylenediamine (2.52 g, 20 mmol) was added portion wise. The resulting reaction 
  53 
mixture was refluxed for about 14 h. The solution was then diluted with water. The 
obtained brown precipitate was filtered and purified by recrystallization from ethanol to 
give 2.5 g of 4-(5-fluoro-1H-benzo[d]imidazol-2-yl)-N,N-dimethylaniline. Nuclear 
magnetic resonance (NMR) spectra were determined in acetone-d6 using a Varian 
instrument (1H, 400 MHz). 1H NMR (400 MHz, DMSO-d6) δ 7.97 (d, J = 8.8 Hz, 2H), 
7.50 (dd, J = 8.4, 4.8 Hz, 1H), 7.32 (dd, J = 9.1, 2.4 Hz, 1H), 7.02 (td, J = 8.6, 2.4 Hz, 
1H), 6.85 (d, J = 8.8 Hz, 2H), 3.01 (s, 6H). Electrospray ionisation mass spectrometry 
(ESI-MS) calculated (M+H)+ 256.1172, found 256.1294. 
 
2.5.3 Cell culture 
All cell lines were purchased from American Type Culture Collection (ATCC, 
Manassas, VA) except for LIM1215 from Sigma-Aldrich (St. Louis, MO). Cells were 
comprehensively authenticated by PCR using human-specific primers and morphology 
checks through microscopes before being frozen as recommended (216), and free of 
mycoplasma from Hoechest 33258 staining (217-218). Each vial of frozen cells was 
thawed and used in experiments for a maximum of 8 wk. Cells were cultured in RPMI 
1640 (DLD1, LIM1215, H838) or MEM (CACO2, LS174T, WiDr, CCD-18Co) or 
McCoy’s 5A (HCT116, HT29) or DMEM (293T) containing penicillin (100 units/mL), 
streptomycin (100 µg/mL), and 10% fetal bovine serum (FBS; Gemini Bio-Products, 
Calabasas, CA). The NIH3T3 cell line was cultured in DMEM with 10% calf serum (CS; 
Gemini Bio-Products). All cells were incubated at 37°C with 5% CO2.  
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2.5.4 Luciferase assay 
Transient transfection was performed using jetPEI (Promega). Assays to detect 
firefly luciferase and Renilla activities were performed according to the manufacturer’s 
manual (Promega). Briefly, cells were seeded onto 10-cm plates and co-transfected with 
400 ng of the Renilla luciferase internal control gene and 4 μg of the TOPFlash luciferase 
reporter construct containing three tandem Tcf consensus binding sites upstream of 
luciferase cDNA, or the FOPFlash luciferase reporter construct, a plasmid with mutated 
Tcf binding sites. After 16 h of transfection, cells were trypsinized and seeded onto 48-
well plates, and then treated with respective compounds for 24 hr. Luciferase and Renilla 
activities were measured using their respective substrates. 
 
2.5.5 MTS assay 
Cells were seeded (1 × 103 cells/well) in 96-well plates, incubated overnight and 
then treated with different doses of HI-B1. After incubation for 2 days, 20 μL of 
CellTiter96 Aqueous One Solution (Promega) were added and then cells were incubated 
for 1 hr at 37°C in a 5% CO2 incubator. Absorbance was measured at 492 nm. 
 
2.5.6 Lentivirus production and infection 
The shRNA of β-catenin clones (sh-ctnnb1 #1: TRCN0000003843, 
AGGTGCTATCTGTCTGCTCTA; #3: TRCN0000003845, 
GCTTGGAATGAGACTGCTGAT; #5: TRCN0000010824, 
CCATTGTTTGTGCAGCTGCTT) were purchased from University of Minnesota 
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Genomics Center (Minneapolis, MN). The lentiviruses were generated from 293T 
packaging cells. The cell culture supernatant fraction containing lentivirus was harvested 
from 293T cells at 24 or 48 hr after transfection. The cells were infected with the 
lentiviruses in the presence of 10 μg/ml of polybrene (Sigma Aldrich, St. Louis, MO). 
After 24 hr of infection, the cells were treated with puromycin for selection, and then 
pooled for subsequent analysis. 
 
2.5.7 Flow cytometry for analysis of apoptosis 
For analysis of apoptosis, cells (1.5 × 105 cells per well) were seeded into six-well 
plates and cultured overnight, then exposed to 50 μM HI-B1 for 48 h. Cells were 
trypsinized, washed twice with cold PBS. They were then resuspended with PBS and 
incubated for 5 min at room temperature with annexin V-FITC plus propidium iodide. 
Cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, 
CA).  
 
2.5.8 Anchorage-independent cell transformation assay  
Cells (8 × 103/well) suspended in 10% Basal Medium Eagle (Sigma Aldrich) 
were added to 0.3% agar with different doses of HI-B1 in a top layer over a base layer of 
0.5% agar with the same concentration of HI-B1. The cultures were maintained at 37°C 
in a 5% CO2 incubator for 1 wk and then colonies were counted under a microscope 
using the Image-Pro Plus software (v.6.1) program (Media Cybernetics, Rockville, MD). 
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2.5.9 7-day proliferation assay 
CACO2 cells were seeded into 6-well plates (2 × 105 cells/well) and cultured with 
or without different doses of HI-B1. After 7 days of incubation, cells were fixed with 4% 
paraformaldehyde (in PBS), and then stained with 0.5% crystal violet (in water) (219). 
 
2.5.10 Foci formation assay 
Transformation of NIH3T3 cells was performing following standard protocols. 
Cells were transiently transfected with combinations of pcDNA3-H-RasG12V (100 ng), 
pcDNA3-β-catenin (1 μg) and pcDNA3-mock (as compensation to achieve equal 
amounts of DNA) plasmids and incubated overnight. Then the cells were cultured in 5% 
CS-DMEM with or without HI-B1 for 2 wk. The media were changed every other day. 
Foci were fixed and stained with 0.5% crystal violet (220). 
 
2.5.11 Western blot analysis  
Cells were disrupted on ice for 30 min in cell lysis buffer (20 mM Tris pH 7.5, 
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium vanadate, and 1 mM PMSF 
[phenylmethylsulfonyl fluoride]) with protease inhibitor cocktail (Roche, Switzerland). 
The supernatant fraction was harvested after centrifugation at 13,000 rpm for 10 min. 
Protein concentrations were determined with the Bio-Rad protein assay reagent 
(Richmond, CA). For nuclear and cytosol fractions, NE-PER Nuclear and Cytoplasmic 
Extraction Reagents (Thermo Scientific, Waltham, MA) were used according to the 
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manufacturer’s protocol. The protein lysates were separated by SDS-PAGE and 
transferred to polyvinylidene fluoride membranes in 20 mM Tris-HCl (pH 8.0), 
containing 150 mM glycine and 15% (v/v) methanol. Membranes were blocked with 5% 
non-fat dry milk in 1 x TBS containing 0.05% Tween 20 (TBS-T) and incubated with 
primary antibodies at 4°C overnight. Protein bands were visualized by the LAS4000 
Biomolecular Imager (GE Healthcare, United Kingdom) and Western Lightning Plus 
ECL (Perkin Elmer, Waltham, MA) after incubation with appropriate secondary 
antibodies. 
 
2.5.12 Quantitative PCR (qRT-PCR) 
Total RNA from cells was extracted using RNeasy Plus Mini Kit (Qiagen, 
Valencia, CA) following the manufacturer’s instructions. The reverse transcription 
reaction was performed with the amfiRivert cDNA Synthesis Platinum Master Mix 
(GenDepot, Barker, TX). Expression of the indicated genes was assessed with a 7500 real 
time PCR system (Applied Biosystems, Carlsbad, CA) using the Power SYBR Green 
Master Mix (Life Technology, Grand Island, NY). Reaction plates were incubated in a 
96-well thermal cycling plate at 95°C for 10 min and then underwent 40 cycles of 15 s at 
95°C and 1 min at 59°C. All reactions were performed in triplicate. Relative quantitation 
(RQ) was calculated using the 2−ΔCt method, where ΔCt symbolizes the change in Ct 
between the sample and reference mRNA. The following primers were used to detect 
expression: GAPDH, 5’-AGCCACATCGCTCAGACAC-3’ (forward), 5’-
GCCCAATACGACCAAATCC-3’ (reverse); cyclin D1, 5’- 
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AGCTCCTGTGCTGCGAAGTGGAAAC -3’ (forward), 5’- 
AGTGTTCAATGAAATCGTGCGGGGT -3’ (reverse); AXIN2, 5’-
CTGGCTCCAGAAGATCACAAAG-3′ (forward) and 5′-
ATCTCCTCAAACACCGCTCCA-3′ (reverse); β-catenin, 5’-
ACCTTTCCCATCATCGTGAG-3′ (forward), 5’-AATCCACTGGTGAACCAAGC-3’ 
(reverse). 
 
2.5.13 Protein purification 
 A construct comprising residues 126-686 of human β-catenin (AB451264) was 
subcloned into pET-46 Ek/LIC vector (EMD Millipore). The recombinant His-fusion β-
catenin was expressed in E.coli BL21 (DE3) and purified by affinity chromatography 
using nickel-nitrilotriacetic acid-agarose. (HisPur™ Ni-NTA, Thermo Scientific).The 
protein was eluted from the resin with 250 mM imidazole, 150 mM NaCl, 20 mM tris, 
pH 8.0, and purified further on a gel-filtration HiLoad 16/60 Superdex-200 column (GE 
Healthcare) equilibrated with buffer (150 mM NaCl, 20 mM CAPS, pH 10.5). 
 
2.5.14 Ex vivo pull-down assays 
Cell lysates (500 µg) were incubated with HI-B1-Sepharose 4B (or Sepharose 4B 
only as a control) beads (50 µL 50% slurry) in reaction buffer (50 mM Tris, pH 7.5, 5 
mM EDTA, 150 mM NaCl, 1 mM DTT, 0.01% NP-40, and 2 mg/mL bovine serum 
albumin). After incubation with gentle rocking overnight at 4°C, the beads were washed 
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3 times with buffer (50 mM Tris, pH 7.5, 5 mM EDTA, 150 mM NaCl, 1 mM DTT, and 
0.01% NP-40) and the binding proteins were visualized by Western blotting. 
 
2.5.15 Co-immunoprecipitation assay 
Cells were treated with the indicated concentrations of HI-B1 for 24 hr and then 
disrupted with lysis buffer. Immunoprecipitation was performed by incubating overnight 
with anti-β-catenin. Protein G Agarose beads (50 μl) (GenDepot, Barker, TX) were added 
and the solution was incubated for 6 hr at 4°C. The beads were washed 3 times with lysis 
buffer. Bound proteins were harvested and visualized by Western blotting. 
 
2.5.16 In silico molecular docking 
The Glide module from Schrödinger Suite 2011 was used for prediction of a small 
molecule-protein binding mode. A crystal structure of a human β-catenin structure (PDB 
ID:1JPW) was downloaded from Protein Data Bank. The binding pocket was selected 
around the K312 and K435 residues, which are reported to be important in the β-
catenin/TCF4 binding mode. The XP (extra precision) docking was repeated more than 
30 times, and the most frequent outcomes of β-catenin in chemical-protein interaction 
were selected as possible binding residues. 
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2.5.17 Animal Experiment protocols 
All animal experiments were reviewed and approved by the Institutional Animal 
Care and Use Committees of the University of Minnesota (Minneapolis, MN) and 
Zhengzhou University (Zhengzhou, Henan, China). 
 
2.5.18 Patient-derived xenografts (PDX) 
Fresh tumor tissue fragments were collected from colon cancer patients and 
transferred at 4°C in FBS-free RPMI 1640 medium with antibiotics. Tumor tissues were 
trimmed into 3–5 mm sizes within 2 hr after surgical resection, and implanted 
subcutaneously in 6 to 8 week-old female SCID mice (Vital River Laboratories Co., Ltd., 
Beijing, China). Once mass formation reached 1500 mm3, mice of this first generation of 
xenografts (named P1) were sacrificed and the tumors were passaged and expanded for 3 
more generations (P2 and P3). When P4 tumors reached an average volume of 50 mm3, 
mice were divided into different groups (n = 8/group) and treated with vehicle or HI-B1 
50 mg/kg, respectively, 3 times a week by oral gavage. HI-B1 was dissolved in 5% 
DMSO and 5% PEG containing PBS. Mice were sacrificed at the end of the experiment 
and tumors extracted. Tumor volume was calculated using the following formula: tumor 
volume (mm3) = (length × width ×height × 0.5). These studies were approved by the 
Ethics Committee of Zhengzhou University. Patients whose tumors were used in these 
studies were completely informed and provided consent. 
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2.5.19 APCmin mouse model 
C57BL ⁄6J-ApcMin/+ mice (APCmin mice, RRID:IMSR_JAX:002020) were 
purchased from the Jackson Laboratory (Bar Harbor, ME), bred and genotyped according 
to the manufacturer’s protocol. Male 6-week-old mice were treated with vehicle or 2 or 
10 mg/kg/day of HI-B1 by oral gavage for 10 weeks (n = 6/group). At the end of the 
experimental period, the intestine and colon were removed, opened longitudinally, and 
fixed flat between filter paper sheets in 10% buffered formalin overnight. These sections 
were stained with a 0.2% methylene blue (Sigma-Aldrich) solution, and the mucosal 
surfaces were assessed for counting polyps with a stereoscopic microscope. One cm-long 
sections were prepared from the same position of ileum across the groups, and mRNA 
was extracted for further real-time PCR analysis. 
 
2.5.20 Immunohistochemistry  
Colon cancer patients-derived xenograft samples were fixed in 10% formalin 
overnight, embedded in paraffin, and sectioned at 5 μm of thickness. The sections were 
stained with haematoxylin and eosin (H&E) according to standard protocols. 
Immunohistochemistry 
staining for β-catenin and c-Myc was performed using an ABC complex kit (PK-6100, 
Vector Laboratories, Burlingame, CA). Harris's haematoxylin was used for counter 
staining. The staining intensity was quantified by calculating the integrated optical 
density (IOD) using the Image Pro-Plus 6.1 software program (Media Cybernetics) (221). 
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Chapter 3: 
The synergistic effect of aspirin and ginger extract 
against colon cancer 
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3.1 Summary 
Colon cancer is the third most diagnosed cancer type in the U.S. Aspirin has 
received a considerable attention due to its anti-cancer effects on colon cancer patients 
with PIK3CA mutations. Ginger extract (GE) has protective effect against aspirin-
induced hemorrhagic ulcer, and active components of GE possess anti-colon cancer 
effects. This led us to investigate on the effects and mechanisms of aspirin and GE 
combination. Co-treatment of aspirin and GE resulted in synergistic cytotoxicity in 
HCT116, DLD1 and HCT15 colon cancer cell lines. The combination treatment caused 
apoptosis by enhancing p53 and p21 protein expressions. 6-Shogaol was identified as an 
active component of GE showing inhibition of anchorage-independent growth and direct 
binding with Akt1/2. In colon cancer patient-derived xenograft (PDX) models, co-
treatment of aspirin 100 mg/kg plus GE 5 mg/kg significantly suppressed tumor growth. 
Of note, tumor-suppressive effects were similar between the combination group and 
aspirin 400 mg/kg group, but weight loss was shown only in aspirin-only group. The 
combination of aspirin and GE could be further exploited for therapeutic applications 
against colon cancer. 
 
 
3.2 Introduction 
Aspirin (acetylsalicylic acid) is one of the most frequently used drugs against 
multiple purposes including pain, fever and inflammatory conditions (222). In past 
decade, the effect of aspirin has been investigated in colon cancer which is the third most 
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common cancer type diagnosed in the United State (223-226). Several lines of studies on 
colon cancer showed that aspirin causes apoptosis and inhibits tumor growth (227-229). 
Especially, aspirin prescription showed a hazard ratio of 0.53 in mortality of colon cancer 
patients who did not use aspirin before the diagnosis (224). However, aspirin has adverse 
effects including hazard ratio of 2.07 in gastrointestinal bleeding even at low doses (230). 
Therefore the dosage reduction which aims the reduction of toxicity while maintaining 
the therapeutic efficacy is important for patients who use aspirin (231). Finding another 
small molecules or drug-like medications will benefit patients who take aspirin for colon 
cancer treatment. 
Phosphoinositide 3-kinase (PI3-K)/Akt/mammalian target of rapamycin (mTOR) 
pathway is a central component of colon cancer progression, and the proteins are 
overexpressed in colon cancer (232). Activated PI3-K/Akt/mTOR signaling results in 
down-regulation of p53, a tumor suppressor (233-234). In colon cancer patients with 
activating mutations on PIK3CA, regular aspirin usage after diagnosis was associated 
with improved colon cancer-specific survival and overall survival (hazard ratio: 0.18, and 
0.54), respectively (235). However, aspirin usage did not improve survival rates in 
PIK3CA-wild type patients (235). This result showed that aspirin exerts its effect against 
colon cancer in which PI3-K/Akt/mTOR pathway is activated. Small molecules that 
inhibit the signaling, such as 6-gingerol targeting Akt1/2 (236), might help aspirin in 
suppressing PIK3CA-mutant tumor growth. 
Ginger (Zingiber officinale Roscoe, Zingiberaceae) is one of the most widely used 
dietary ingredients worldwide in the forms of condiment, tea or extracts (237-238). 
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Ginger is reported to be effective not only for ulcerative colitis and inflammation, but for 
treatment against cancer (237). Ginger powder reduced aspirin-induced hemorrhagic 
ulcer in stomach of rats (239). Ginger extracts (GE) and its active constituents, 6-gingerol 
and 6-shogaol, showed inhibitory effects against colon cancer (240-242). 6-Gingerol 
inhibited the tumor growth of HCT116 colon cancer cell xenograft by directly binding 
with leukotriene A4 (241). 6-Shogaol suppressed HT-29 colon cancer cell growth by 
activating peroxisome proliferator-activated receptor γ (242). The anti-ulcer and anti-
cancer effects of ginger showed the possibility that ginger might reduce the toxicity of 
aspirin while maintaining the efficacy of aspirin. However, the combination of ginger 
extracts (GE) and aspirin and their molecular mechanism against colon cancer are still 
remained unclear. 
Herein, we tested the combination of GE and aspirin against colon cancer cells in 
vitro and in vivo. Treatment of GE or aspirin inhibits proliferation and anchorage-
independent growth of HCT116, DLD1 and HCT15 colon cancer cell lines. When treated 
in combination, GE and aspirin exerts synergistic effects against the colon cancer cell 
growth. Co-treatment of GE and aspirin significantly increases apoptosis and increased 
protein expression levels of p53 and p21. High-performance liquid chromatography 
(HPLC) analysis reveals that 6-gingerol, 6-shogaol, 8-gingerol and 10-gingerol are major 
components of GE. Among the four compounds, 6-shogaol shows the strongest inhibitory 
effects against colon cancer. GE and 6-shogaol directly binds to Akt1/2. Colon cancer 
patient-derived xenograft (PDX) results show that co-treatment of aspirin 100 mg/kg and 
GE 5 mg/kg has similar therapeutic effects compared to aspirin 400 mg/kg treatment.  
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3.3 Results 
3.3.1 Ginger extract and aspirin inhibit anchorage-independent growth 
and cell proliferation of HCT116, DLD1 and HCT15 colon cancer cell 
lines. 
Based on the selective effect of aspirin on PIK3CA-mutant colon cancer patients 
(235), we chose HCT116, DLD1 and HCT15 colon cancer cell lines in where PIK3CA 
mutations are present (243-244). Aspirin and GE were tested on anchorage-independent 
growth and cell proliferation to confirm their effects (245-246) and calculate IC50 values 
that are needed for combination analysis (231). IC50 of aspirin on inhibiting anchorage-
independent cell growth were 1.7, 1.9 and 2.2 mM in HCT116, DLD1 and HCT15 cell 
lines, respectively (Figure 3.1a). GE also inhibited anchorage-independent growth of the 
three colon cancer cells showing IC50 values of 2.3, 5.2 and 6.8 μg/ml, respectively 
(Figure 3.1b). In cell proliferation assay that cells are grown in anchorage-dependent 
condition, aspirin also inhibited the proliferation of HCT116, DLD1 and HCT15 cell 
lines (IC50: 2,4, 3.0 and 2.5 mM; Figure 3.1c). GE showed its inhibitory effects on cell 
proliferation showing higher IC50 values compared to the soft agar assay (IC50: 24, 38 
and 31 μg/ml; Figure 3.1d). These result showed that aspirin and GE can suppress colon 
cancer growth when treated individually. 
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Figure 3.1a The effect of aspirin on anchorage-independent growth of HCT116, HT29 
and DLD1 cell lines. The numbers of colonies were counted after 5-10 days. 
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Figure 3.1b The effect of ginger extract (GE) on anchorage-independent growth of 
HCT116, HT29 and DLD1 cell lines. The colonies were counted after 5-10 days. 
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Figure 3.1c The effect of aspirin on cell proliferation. Cells were treated with aspirin (0-5 
mM) and proliferation was determined at the indicated time points by MTS assay.  
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Figure 3.1d The effect of GE on cell proliferation. Cells were treated with GE (0-40 
µg/ml) and proliferation was determined at the indicated time points by MTS assay.  
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3.3.2 Ginger extract and aspirin show synergistic effects when co-
treated to colon cancer cells. 
We next focused on the combinational effects of aspirin and GE. Different doses 
of GE were co-treated with aspirin and their efficacy was tested in anchorage-
independent colon cancer cell growth. The percentage of the inhibition (Fraction affected: 
Fa) was then calculated to measure combination index (CI) which determines 
antagonism, additive effect and synergism between combinational treatments (231). 
Based on IC50 values of ginger extract and aspirin mentioned above, CI of co-treatment 
groups were determined. CI result showed that ginger extract and aspirin are synergistic 
when treated together against anchorage-independent cell growth of cancer cells (Figure 
3.2a). Of particular note, the two treatments were more synergistic together at higher 
dosages resulting in CI of 0.1 to 0.3 which indicates very strong synergism. Formazan 
production assay also showed that 20 μg/ml of GE treatment can reduce IC50 value of 
aspirin from 2.28 to 0.66 mM (Figure 3.2b). We sought to find if the combination 
treatment triggers apoptosis, a programmed cell death. When treated individually, aspirin 
5 mM treatment increased apoptosis by 4% and GE 15 μg/ml increased apoptosis by 9% 
in HCT116 cell line (Figure 3.2c). The combination treatment of aspirin and GE showed 
26% increase of apoptosis. Protein expression of p53 and p21, tumor suppressors, were 
increased in aspirin and GE combination group (Figure 3.2d). This result supports the 
synergistic effect of aspirin and GE against colon cancer cell growth. 
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Figure 3.2a Aspirin and ginger extract (GE) combination shows strong synergistic effect. 
HCT116, DLD1, HCT15 cells were treated with different combinations of aspirin and GE 
for 5-10 days and then colonies were counted. The number of colonies was converted 
into affected fraction (Fa) among total cell population. Combination index (CI) was 
calculated according to Materials and Methods. CI values less than 0.85 indicate 
synergistic effect.  
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Figure 3.2b The effect of GE on IC50 values of aspirin. Aspirin and GE were co-treated 
to HCT116 cells for 72h at different concentrations, and IC50 values of aspirin at 
presence of GE were calculated. 
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Figure 3.2c The effects of aspirin and GE on apoptosis. Aspirin and/or GE were treated 
for 72h. Apoptosis was measured with flow cytometry. The asterisk (*) indicates a 
significant decrease compared with untreated control (p < 0.05). 
 
 
Figure 3.2d The effects of aspirin and GE on p53 and p21 expression levels. Aspirin 
and/or GE were treated for 72h and protein lysates were analyzed by western blots. 
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3.3.3 6-Shogaol, a major component of the GE, shows inhibitory effect 
against anchorage-independent growth of HCT116. 
To elucidate details of the anti-cancer effect of GE, we sought to find the major 
ingredients of the extract. High-performance liquid chromatography (HPLC) result 
showed that 6-gingerol, 6-shogaol, 8-gingerol and 10-gingerol are four major components 
of the GE (Figure 3.3a and b). 6-Gingerol was the most abundant small molecule among 
the components, followed by 6-shogaol, 8-gingerol and 10-gingerol (Table 3.1). Based on 
the HPLC result, GE was reconstituted with the relative concentrations of the four major 
ingredients and tested in anchorage-independent growth and cell proliferation of HCT116 
DLD1 (Figure 3.3c and d). Reconstituted ginger extract was similar to the original ginger 
extract. Among the four components, 6-shogaol had the strongest inhibitory effect against 
the cell growth of HCT116. Based on the previous finding that 6-shogaol possesses its 
anti-cancer effect by directly targeting Akt1/2 (236), we tested the ability of ginger 
extract and its major components to bind with Akt. Binding assay using sepharose 4B 
beads showed that GE and 6-shogaol directly bound to Akt1/2 (Figure 3.3e). 
Interestingly, 8-gingerol was able to bind with Akt, but 6-gingerol and 10-gingerol could 
not bind to the protein. Overall, the previous study and this result indicate that the anti-
cancer effect of GE is derived from one of its active component, 6-shogaol, and that PI3-
K/Akt pathway might be the signaling targeted by GE.  
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Figure 3.3a Chemical structures of four major ginger componets, 6-shogaol, 6-gingerol, 
8-gingerol, and 10-gingerol. 
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Figure 3.3b HPLC chromatograms of ginger extract. GE peaks were compared with 
those of 6-shogaol, 6-gingerol, 8-gingerol, and 10-gingerol (1 mM). 
 
 
 
Table 3.1 Contents of GE. The amounts of components (μg/mg GE extract) were 
presented. 
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Figure 3.3c The effects of GE ingredients on anchorage-independent growth of HCT116 
cells. Cells were treated with 6-shogaol, 6-, 8-, and/or 10 gingerol, or ginger extract and 
colonies were counted after 7 days. 
 
 
Figure 3.3d The effects of GE ingredients on HCT116 cell proliferation. Cells were 
treated with 6-shogaol, 6-, 8-, and/or 10 gingerol, or ginger extract and proliferation was 
determined at 72h by MTS assay.  
  79 
 
 
 
 
 
 
Figure 3.3e Ginger extract, 6-shogaol and 8-gingerol interact with Akt. Whole-cell 
lysates from HCT116 cells (500 μg) were incubated with control or chemical-conjugated 
Sepharose 4B beads, and then proteins bound to the beads were analyzed by western 
blotting. 
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3.3.4 Inhibition of PI3-K pathway can mimic the combination effect of 
ginger extract and aspirin. 
Next, we sought to further confirm the combination effect of ginger extract and 
aspirin by mimicking the PI3-K/Akt pathway inhibition using LY294002, a PI3-K 
inhibitor. Co-treatment of LY294002 and aspirin also showed synergistic effects on 
inhibition of HCT116, DLD1 and HCT15 colon cancer cell growth (Figure 3.4). This 
result supports the synergistic effect of aspirin and GE, and suggests that GE can reduce 
aspirin dosage by inhibiting PI3-K/Akt pathway. 
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Figure 3.4 Aspirin and LY294002 combination shows synergistic effect. HCT116 cells 
were treated with aspirin (0-4 mM) and LY294002, a PI3K/Akt inhibitor, (0-40 µM) for 
72 h and then proliferation was determined by MTS assay. 
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3.3.5 Ginger extract reduces aspirin dosage in tumor growth inhibition 
of colon cancer patient-derived xenograft (PDX) models. 
Two different xenograft tumors from colon cancer patients (JG14 and JG17) were 
prepared subjected to aspirin and/or GE treatment. 400 mg/kg of aspirin treatment 
inhibited the PDX tumor volume (Figure 3.5a and b) and weight (Figure 3.5c and d). 20 
mg/kg of GE treatment also showed moderate inhibitory effect against the PDX tumor 
growth, but the effect was weaker than that of aspirin. When treated in combination, 100 
mg/kg of aspirin and ginger extract and 5 mg/kg of ginger extract exerted similar efficacy 
of 400 mg/kg of aspirin treatment on tumor volume and weight (Figure 3.5a-d). Of 
particular note, 400 mg/kg of aspirin decreased body weight of mice whereas the 
combination treatment did not show the adverse effect (Figure 3.5e and f). Adding 5 
mg/kg of ginger extract could save 300 mg/kg of aspirin treatment while retaining the 
efficacy against colon cancer PDX tumor growth. Overall, this in vivo result shows that 
ginger extract can reduce the dosage of aspirin in colon cancer therapy. 
  83 
 
Figure 3.5a The effect of aspirin and GE against JG14 colon cancer PDX tumor volume. 
Aspirin and/or GE were dissolved in normal saline and administered p.o. 5 times/wk. 
Tumor size was measured three times a week. One-way ANOVA and Dunnett’s test after 
log-transformation; *P < 0.05, significant difference compared to the vehicle group. 
 
 
Figure 3.5b The effect of aspirin and GE against JG17 PDX tumor volume. 
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Figure 3.5c The effect of aspirin and GE against JG14 colon cancer PDX tumor weight. 
Aspirin and/or GE were dissolved in normal saline and administered p.o. 5 times/wk. 
Tumor weight was measured at the end of experiments, and representative tumor photos 
were taken.  
 
          
Figure 3.5d The effect of aspirin and GE against JG17 colon cancer PDX tumor weight. 
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Figure 3.5e The effect of aspirin and GE against body weight of mice bearing JG14 PDX 
tumor. Aspirin and/or GE were dissolved in normal saline and administered p.o. 5 
times/wk. 
 
 
Figure 3.5f The effect of aspirin and GE against body weight of mice bearing JG17 PDX 
tumor. 
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3.4 Discussion 
This study aimed to find a supplement that helps aspirin in suppressing colon 
cancer growth and elucidate their combination effects. Herein, we found that GE showed 
inhibitory effects on colon cancer cell growth, and clearly demonstrated that aspirin and 
GE has synergistic effect when treated together. The molecular mechanism of GE was 
investigated and revealed its active component, 6-shogaol, inhibited PI3-K/Akt pathway. 
The synergistic effect was further confirmed by aspirin-LY294002 combination that also 
showed synergism against colon cancer growth. The cooperative relationship of aspirin 
and GE was tested in colon cancer PDX models. Aspirin 100 mg/kg plus GE 5 mg/kg 
treatment was similarly effective as aspirin 400 mg/kg treatment. Notably, the aspirin 
dosage reduction by GE helped preventing weight loss that was shown at the high-dose of 
aspirin treatment. This work highlighted that GE, a food-derived supplement, can aid the 
anti-cancer effect of aspirin by inhibiting PI3-K pathway. 
PI3-K pathway is one of main streams in where driver mutations are frequently 
found. Loss-of-function mutations in Phosphatase and Tensin Homolog (PTEN) (247) 
and gain-of-function mutations on PI3-K (248-249), Akt (250), and mTOR (251) 
facilitate carcinogenesis and tumor growth. Aspirin was selectively effective on PI3-K-
activated tumor growth in mice (246) and colon cancer patients (235). Inhibition of 
mTORC1 signaling by aspirin also supports the underlying mechanisms of the clinical 
data (252-253). The synergistic effect of aspirin and GE inhibiting PI3-K pathway 
corresponds to Loewe additivity model that assumes two inhibitors act through a similar 
mechanism (254-255). When combination index was calculated following the model, 
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aspirin and GE showed synergism in suppressing colon cancer cell growth. The strong 
synergism at higher concentrations of aspirin and GE (Figure 3.2a) also support the 
model that targeting different levels of a single pathway can lead to synergistic effect and 
increase of clinical efficacy (255). 
Precision medicine is becoming a new standard for cancer therapy. Prescribing 
the best drug for individuals increased efficacy and lowered adverse effects compared to 
so-called "one-size-fits-all" strategy (9). The selective effect of aspirin in colon cancer 
patients with PIK3CA-mutations but not ones without the mutations (235) reveals that 
aspirin will be widely used for patients with PIK3CA-mutated colon cancer. Our work 
suggests that adding GE to aspirin treatment might be helpful on reducing the dose of 
aspirin. PDX data showed that low dose of aspirin and GE combination is as potent as 
high dose of aspirin, and that the combination helps avoiding adverse effects such as 
weight loss (Figure 3.5). This result highlights that ginger extract might be helpful to 
patients who take aspirin as a therapeutic measure for PI3-K-activated colon cancer. 
 
 
3.5 Materials and Methods 
3.5.1 Cell culture, antibodies and reagents 
HCT116 cells were cultured in McCoy's 5a Medium/10% FBS with antibiotics. 
DLD1 and HCT15 cells were cultured in RPMI-1640/10% FBS with antibiotics. All cell 
lines were purchased from American Type Culture Collection (ATCC, Manassas, VA) 
and cytogenetically tested and authenticated before the cells were frozen. Each vial of 
  88 
frozen cells was thawed and maintained for a maximum of 8 weeks. Anti-p53 (DO-1), 
anti-p21 and anti-β-actin were purchased from Santa Cruz (Dallas, TX). Anti-Akt 
antibody is from Cell Signaling (Danvers, MA). Ginger extract (256) was obtained from 
Sabinsa Corporation (Piscataway, NJ). 6-Shogaol (purity > 96%) was synthesized as 
described earlier (236) and were analyzed and authenticated by high-performance liquid 
chromatography (HPLC). 6-, 8- and 10-Gingerol (purity > 95%) were purchased from 
Dalton Chemical Laboratories (Toronto, Canada).  
 
3.5.2 Anchorage-independent cell growth assay 
Cells (8×103 per well) were suspended in basal medium eagle (BME) containing 
10% FBS and 0.3% agar and plated on solidified BME containing 10% FBS and 0.5% 
agar. After incubation for 4-10 days, the colonies were counted under a microscope using 
the Image-Pro Plus Software (v.6.1) program (Media Cybernetics, Rockville, MD).  
 
3.5.3 Cell proliferation assay 
Cells (3×103 per well) were seeded in 96-well plates and then cell proliferation 
was determined using the CellTiter 96 AQueous Non-Radioactive Cell Proliferation 
Assay kit (Promega, Madison, WI) according to the manufacturer’s instructions. This kit 
is composed of tetrazolium compound (3-(4,5--dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) and an 
electron-coupling reagent (phenazine methosulfate; PMS). MTS is converted into a 
formazan by dehydrogenase found in metabolically active cells, and the quantity of 
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formazan product is directly proportional to the number of living cells. 
 
3.5.4 Synergy assessment 
 Combination index (CI) was used to quantify synergism or antagonism for two 
drugs (231, 257), CI = (D)1/(Dx)1 + (D)2/(Dx)2 where CI < 1, =1, and > 1 indicate 
synergism, independence, 
and antagonism, respectively. In the denominators, (Dx)1 represents D1 “alone” that 
inhibits a system x%, and (Dx)2 is for D2 “alone” that inhibits a system x%. In the 
numerators, (D)1 and (D)2 “in combination” also inhibit x%. CI was calculated for every 
dose of two drug pairs. Fraction affected (Fa) is the fractional inhibition of a phenotype 
by a compound treatment(s). 
Fa of a group was calculated as Fa = percent inhibition of cell viability/100. Fraction 
affected-combination index plot was drawn with every group treated with more than one 
compound. 
 
3.5.5 Apoptosis assay 
Cells (1×105 per well) were seeded in 6-cm dishes and then apoptosis was 
analyzed by a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) using the 
Annexin V-FITC apoptosis detection kit (MBL International Corp., Woburn, MA). 
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3.5.6 HPLC analysis of ginger extract 
Ginger extract was dissolved in DMSO and then injected into a high performance 
liquid chromatography system equipped with a reverse-phase column (Luna® 5 µm C18 
100 Å, LC Column 250 x 4.6 mm, Phenomenex, Torrance, CA). Ginger components 
were eluted at a flow rate of 1 ml/min using 65% acetonitrile in water (solvent A) and 
93% methanol in water (solvent B) stepped gradient programs. Gradient elution was 
performed as follows: 50% B to 100% B in 5 min/100% B for 7 min/ 100% B to 50 % B 
in 2 min/ 50% B equilibration for 10 min. 6-Shogaol, 6-, 8-, and 10-gingerol were 
identified by their retention times and quantified by comparison with standards, and their 
levels were expressed as concentration values in µg/mg of ginger extract.  
 
3.5.7 Binding assay 
All of ginger components-conjugated Sepharose 4B beads were prepared as 
described previously (Cancer Res. 2010 Dec 1;70(23):9755-64). A whole cell lysate from 
HCT116 cells (500 mg) was incubated with resveratrol-conjugated or control beads at 
4°C overnight in NP-40 lysis buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM 
EDTA, 0.5% NP-40 and protease inhibitor]. After washing 5 times with NP-40 lysis 
buffer, the proteins bound to the beads were analyzed by Western blotting.  
 
3.5.8 Western blotting 
Cells were harvested and disrupted with NP-40 lysis buffer. The supernatant 
fraction was harvested after centrifugation at 13,000 rpm for 10 min. Protein 
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concentration was determined by Bio-Rad protein assay reagent (Richmond, CA). Whole 
cell lysates were subjected to SDS-PAGE and transferred to a polyvinylidene difluoride 
membrane (Millipore, Billerica, MA). After blocking with 5% non-fat dry milk in 1 x 
TBS containing 0.05% Tween 20 (TBS-T), the membrane was incubated with a specific 
primary antibody, and then protein bands were visualized with the ECL system and 
LAS4000 Biomolecular Imager (GE Healthcare, UK) after hybridization with a 
horseradish peroxidase-conjugated secondary antibody.   
 
3.5.9 Patient-derived Xenograft (PDX) 
Fresh tumor fragments were collected from colon cancer patients and transferred 
in RPMI 1640 medium with antibiotics at 4°C. The tumor tissues were trimmed into 3–5 
mm sizes within 2 hr after surgical resection, and implanted to 6 to 8 week-old female 
SCID mice subcutaneously (Vital River Laboratories Co., Ltd., Beijing, China). Once 
mass formation reached 1,500 mm3, mice of the first generation of PDX (named P1) were 
sacrificed and the tumors were segmented and expanded for 3 more generations (P2 and 
P3). When P4 tumors reached an average volume of 50 mm3, mice were divided into 
different groups (n = 10/group) and treated with vehicle or aspirin 400 mg/kg or GE 20 
mg/kg or aspirin 100 mg/kg+GE 5 mg/kg, respectively, 5 times a week by oral gavage. 
Aspirin and GE were dissolved in 0.9% saline. Mice were sacrificed at the end of the 
experiment and tumors extracted. Tumor volume was calculated using the following 
formula: tumor volume (mm3) = (length × width ×height × 0.5). All studies were 
reviewed and approved by the Ethics Committee of Zhengzhou University. Patients 
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whose tumors were used in these studies were completely informed and provided 
consent. 
 
3.5.10 Statistical analysis  
All quantitative results are expressed as mean values ± S.D. Statistically 
significant differences were obtained by one-way ANOVA. ANOVA with Dunnett’s test 
was used for multiple comparisons within experiments. A p-value of < 0.05 was 
considered to be statistically significant. 
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Chapter 4: 
Multiple phytochemicals at low doses 
accumulatively inhibit one key protein in cancer 
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4.1 Summary 
Fruits and vegetables are good sources of phytochemicals that possess health-
promoting effects such as reducing the risk of cancer. Although the anti-cancer effects of 
phytochemicals are heavily investigated, there exists a limitation that a single 
phytochemical is not correlated with reducing risks of cancer. This is partly due to the 
low concentration of each phytochemical in our body. To tackle this issue, we 
hypothesized that many phytochemicals with similar chemical structure may have a same 
target protein and the natural compounds, although at low doses, can inhibit the activity 
of the protein to where the anti-cancerr effects are focused. From chemical similarity 
analysis of four known ERK inhibitors, we found six new ERK2 inhibitors with similar 
chemical structures. The ten phytochemicals were able to accumulatively inhibit ERK2 
activity in vitro. ERK inhibitor mixture that each phytochemical exists at a low 
concentration suppressed H-ras-induced cell transformation of fibroblast, and inhibited 
anchorage-independent growth of cancer cells in where ERK2 is essential and highly 
expressed. This work will impact the cancer community by showing that many natural 
compounds can work together targeting ERK2, an important target in cancer.  
 
 
4.2 Introduction 
Fruits and vegetables are good sources of phytochemicals and believed to possess 
health-promoting effects such as reducing the risk of cancer (258-259). For example, a 
cohort study showed that high cruciferous vegetable consumption may reduce the risk of 
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bladder cancer (258). People are encouraged to intake more fruits and vegetables under 
so-called “five-a-day” campaign (260) and epidemiological data showed that a diet with 
higher fruit, vegetable and fiber than five-a-day diet may reduce adverse effects among 
breast cancer survivors (261). When it comes to molecular mechanisms, however, there 
exists a limitation that the health-promoting effect cannot be explained by a single 
phytochemical. Although many basic researches reveal anti-cancer effects of 
phytochemicals, especially elucidating target proteins of the small molecules (262). the 
physiological concentration of one phytochemical is often too low to expect any effect. 
An alternative model that uses low doses of phytochemicals naturally abundant might be 
helpful to better understand anti-cancer effects of phytochemicals. 
Extracellular signal–regulated kinase 2 (ERK2) is a protein kinase receiving 
signals under Ras/Raf/ Mitogen-activated protein kinase kinase (MEK) pathway, and 
involved in carcinogenesis and cancer cell proliferation (263).  ATP binding site of ERK 
is a concave protein surface ideal for direct interaction by small molecules (264). 
Recently natural small molecules that can suppress ERK activity were reported such as 
catechol (265), (+)-2-(1-hydroxy-4-oxocyclohexyl) ethyl caffeate (HOEC) (266), caffeic 
acid (267) and norathyriol (268). Catechol suppresses growth of lung cancer patient-
derived xenograft (PDX) tumors by directly targeting ERK (265). HOEC, caffeic acid 
and norathyriol suppress solar UV-induced skin carcinogenesis in SKH-1 hairless mice 
by direct ERK inhibition (266-268). Therefore, targeting ERK with phytochemicals 
might be an effective strategy for preventing and treating cancer. 
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Herein, we tested our hypothesis that phytochemicals at low doses can 
accumulatively inhibit one protein. Chemical similarity analysis of four ERK2 inhibitors 
leads to determination of the crystal structure of ERK2 bound with 5,6-
dihydroxychromone (5,7-DHC). Fisetin, quercetin, luteolin, 7,3’,4’-THIF and cyanidin 
were also identified as direct ERK2 inhibitors after in vitro. Using the ten natural ERK2 
inhibitors in mixture (Ei-mix), we prove that natural compounds at low doses can 
accumulatively inhibit ERK2. Ei-mix suppresses H-ras-induced cell transformation in 
NIH3T3 cells, and inhibits anchorage-independent growth of K562 and SK-MEL-28 cells 
in where ERK2 is essential and highly expressed. Signaling pathway is also analyzed to 
show that phosphorylation of ERK2 substrates were decreased by Ei-mix treatment. 
 
 
4.3 Results 
4.3.1 Chemical similarity analysis of known ERK2 inhibitors leads to 
determination of the crystal structure of ERK2 in complex with 5,7-
dihydroxychromone. 
Accumulative evidence shows that natural phytochemicals interfere oncogenic 
signaling pathways by directly targeting proteins (262, 269). ERK2 (extracellular signal-
regulated kinase 2), for example, is one of key proteins in carcinogenesis and directly 
inhibited by naturally-occurring small molecules such as catechol (PDB ID: 4ZXT) 
(265), HOEC (266), caffeic acid (PDB ID: 4N0S) (267) and norathyriol (PDB ID: 3SA0) 
(268) (Figure 4.1a). We hypothesized that there will be more natural ERK2 inhibitors 
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with similar chemical structures. Chemical clustering of the four phytochemicals showed 
that catechol, HOEC and caffeic acid formed one cluster, and norathyriol composed the 
other cluster (Figure 4.1b). We next sought to find phytochemicals which are similar to 
norathyriol from SuperNatural Ⅱ, a database with more than 325,000 natural compounds 
(270). By applying Tanimoto index, a popular method to quantify the similarity of two 
molecules, and threshold value of 0.9 (271-273), 14 compounds were found to be similar 
to norathyriol (Figure 4.1c). Twelve compounds were xanthone including norathyriol 
itself (1,3,6,7-tetrahydroxyxanthone), and the other two were chromone. After excluding 
xanthones that might be less innovative, 5,7-dihydroxychromone (5,7-DHC) was tested 
on co-crystallization with ERK2. We were able to resolve a crystal structure of ERK2 
bound with 5,7-DHC in the ATP binding site at 1.4 Å resolution (Figure 4.1d). 
Superimposition of current structure with norathyriol-bound ERK2 (PDB ID: 3SA0) 
structure showed that 5,7-DHC and norathyriol occupy the same position in the ATP 
binding site (See Figure 4.1e).  
 
 
Figure 4.1a Chemical structures of previously reported ERK2 inhibitors. 
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Figure 4.1b Small molecule clustering of the four ERK inhibitors. The hierarchical 
clustering was carried out using Canvas in from Schrödinger Suite 2016. Distance matrix 
was used to generate the dendrogram. 
 
 
Figure 4.1c Chemical similarity analysis of norathyriol. Tanimoto similarity coefficients 
of natural compounds compared to norathyriol were calculated from SuperNatural Ⅱ 
database. Tanimoto threshold 0.9 was used to determine similar chemicals. 
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Figure 4.1d The crystal structure (1.4 Å resolution) of ERK2 bound with 5,7-DHC 
(blue). 5,7-DHC bound to the ATP binding site of ERK2. 
 
 
Figure 4.1e Superimposition of current structure with norathyriol-bound ERK2 (PDB ID: 
3SA0) structure. Norathyriol is depicted in yellow.
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4.3.2 Identification of compounds with inhibitory effects on ERK2 
kinase activity. 
We next focused on the identification of ERK2 inhibitors based on chemical 
similarity with catechol and 5,7-DHC. There were 2,720 natural compounds that have 
catechol moiety, and 3,978 compounds with 5,7-DHC moiety (Figure 4.2a). To increase 
the possibility of identifying ERK2 inhibitors, compounds with catechol moiety and 5,7-
DHC (or chromone) moiety were selected and subjected to ERK2 in vitro kinase assay. 
Fisetin, quercetin, luteolin, 7,3’,4’-trihydroxyisoflavone (7,3’,4’-THIF) and cyanidin 
inhibited ERK2 kinase activity in vitro (Figure 4.2b and c). However, procyanidin B2, a 
dimer form of cyanidin, was not able to reduce ERK2 activity (Figure 4.2c). We 
postulated that the compound is too bulky to fit into the ATP binding site of ERK2.  
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Figure 4.2a Substructure search results from SuperNatural Ⅱ database. 2,720 natural 
compounds with catechol substructure were found. There were 3,978 compounds with 
5,7-DHC substructure. To enhance the chance to find ERK2 inhibitor, compounds with 
catechol substructure and 5,7-DHC (or chromone) substructure were selected for in vitro 
ERK2 kinase screening. Fisetin, quercetin, luteolin, 7,3’,4’-THIF, cyaniding and 
procyanidin B2 were chosen. 
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Figure 4.2b Validation assay of predicted ERK2 compounds. Elk1 fusion protein was 
used in an in vitro kinase assay with active ERK2. Results were visualized by applying p-
Elk1 antibody and western blots. Coomassie brilliant blue staining served as a loading 
control.  
 
   
Figure 4.2c Validation assay of predicted ERK2 compounds (continued). 
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4.3.3 Fisetin, quercetin, luteolin, 7,3’,4’-THIF and cyanidin directly 
bind to ERK2 and inhibit its kinase activity in a dose-dependent 
manner. 
To further confirm the in vitro kinase screening, the activity of fisetin, quercetin, 
luteolin, 7,3’,4’-THIF and cyanidin were examined at different doses. The five 
compounds were able to reduce ERK2 kinas activity in a dose-dependent manner (Figure 
4.3a-e). Of note, the phytochemicals showed similar IC50 values (fisetin: 7.0, quercetin: 
8.8, luteolin: 8.6, 7,3’,4’-THIF: 12.9, cyanidin: 9.3 μM) supporting similar property 
principle which refers that structurally similar molecules tend to have similar properties 
(274). Binding assay using sepharose 4B beads showed that the five compounds directly 
bound to ERK2 (Figure 3f). Throughout chemical similarity analysis of four ERK2 
inhibitors previously reported (catechol, HOEC, caffeic acid and norathyriol), six new 
phytochemicals (5,7-DHC, fisetin, quercetin, luteolin, 7,3’,4’-THIF and cyanidin) were 
newly identified as ERK2 inhibitors.  
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Figure 4.3a-e Newly identified natural compounds inhibit ERK2 kinase activity in vitro. 
RSK2 fusion protein was used in an in vitro kinase assay with active ERK2. 5-20 μM of 
Fisetin (a), quercetin (b), luteolin (c), 7,3’,4’-THIF (d) and cyanidin (e) were tested. 
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Figure 4.3f The newly identified compounds bind to ERK2 ex vivo. A whole cell lysate 
was incubated with 100 μl of phytochemical-conjugated Sepharose 4B and sepharose 4B 
(negative control) beads in 500 ml of reaction buffer. Pulled down proteins were detected 
by Western blotting. Caffeic acid and catechol served as positive controls. 
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4.3.4 Natural ERK2 inhibitors at low doses accumulatively inhibit 
ERK2 kinase activity and H-ras-induced cell transformation. 
The ten phytochemicals that directly inhibit ERK2 activity were mixed to 
constitute ERK2 inhibitor mixture (Ei-mix) to better mimic the condition that people 
consume different fruits and vegetables daily. In vitro kinase assay showed that 20 μM of 
EI-mix (10 compounds, 2 μM each) inhibited the phosphorylation of RSK2, a substrate 
of ERK2 (Figure 4.4a). When each compound was removed one by one, the inhibitory 
effect was diminished. This result proved the hypothesis that phytochemicals at low 
doses can accumulatively inhibit one protein. Next we sought to test the effect Ei-mix on 
cell transformation induced by H-ras, an upstream of ERK2. As previously reported 
(275), constitutively-activated H-ras (G12V) induced foci formation (Figure 4.4b). Ei-
mix was able to suppress H-ras-induced cell transformation of NIH3T3 cells in a dose-
dependent manner (Figure 4.4c). This result highlights the possibility that phytochemicals 
in nature, although at low doses, can exert their anti-cancer effects if the small molecules 
with similar structures focus their effect on one key protein. 
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Figure 4.4a Natural ERK2 inhibitors at low doses accumulatively inhibit ERK2 kinase 
activity. RSK2 fusion protein was used in an in vitro kinase assay with active ERK2. Ten 
phytochemicals were at 2 μM each, to make 20 μM concentrations as Ei-mix. Each 
compound was replaced with DMSO one by one. Results were visualized by 
autoradiography. Coomassie brilliant blue staining served as a loading control. 
CAY10561 is a positive control. 
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Figure 4.4b H-ras-induced foci formation assay. Foci formation assay was carried out 
following a protocol described in Materials and Methods. Foci were stained with 0.5% 
crystal violet after 2 wk-long incubation. 
 
 
Figure 4.4c The effect of Ei-mix on H-ras-induced foci formation. Foci formation assay 
was carried out following a protocol described in Materials and Methods. Foci were 
stained with 0.5% crystal violet after 2 wk-long incubation. Media with different 
concentration of Ei-mix was prepared by serial dilution from 20 μM. Media was changed 
every other day.  
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4.3.5 Ei-mix inhibits the phosphorylation of ERK2 substrates and 
colony formation of K562 and SK-MEL-28 cell lines in where ERK2 is 
highly expressed and critical for growth. 
Because ERK2 is an important cell signaling mediator for proliferation of cancer 
cells (276-277), cell lines with high expression level of ERK2 serve as a useful platform 
to test the efficacy of Ei-mix. Analysis of mRNA expression and copy number of ERK2 
in 1,036 cancer cell lines (278) showed that K562 and SK-MEL-28 might have high-
ERK2 levels whereas H1650 and SH SY5Y might have low-ERK2 levels (Figure 4.5a). 
Western blot analysis confirmed that the former cell lines express higher ERK2 protein 
levels compared to the latter ones (Figure 4.5b). K562 and SK-MEL-28 cell lines 
proliferated rapidly compared to H1650 and SH SY5Y cell lines in anchorage-
independent conditions (Figure 4.5c). Knock-down of ERK2 inhibited anchorage-
independent growth of K562 and SK-MEL-28 cells (Figure 4.5d). Treatment of Ei-mix 
suppressed anchorage-independent growth of K562 and SK-MEL-28 cell lines (Figure 
4.5e). Subsequent western blot analysis showed that the phosphorylation levels of RSK2 
and c-Myc were reduced by Ei-mix treatment in a dose-dependent manner (Figure 4.5f). 
Collectively, our results show that phytochemicals that have similar structure compared 
to known ERK2 inhibitors also possess inhibitory effects against ERK2 kinase activity. 
And this provides a physiologically-relevant model of phytochemicals against cancer 
(Figure 4.6). Naturally-occurring small molecules with similar structures can 
accumulatively inhibit ERK2 (Table 4.1). 
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Figure 4.5a ERK2 expression analysis from cancer cell line encyclopedia (CCLE). 
mRNA expression and copy number of ERK2 in 1,036 cancer cell lines were downloaded 
from CCLE database. 
 
 
Figure 4.5b Validation of ERK2 expression levels in four cell lines. Four different cell 
lysates were subjected to western blots with ERK2 antibody. β-actin served as a loading 
control. 
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Figure 4.5c ERK2-high cell lines proliferate faster in the anchorage-independent growth 
condition. Same number of cells from the four different cell lines was suspended in 0.3% 
agar-containing media. Numbers of colonies were calculated after 7 days of incubation. 
 
   
Figure 4.5d The effect of knock-down of ERK2 in K562 and SK-MEL-28 cell lines. 
Two different shRNA sequences targeting ERK2 were used to knock-down. 
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Figure 4.5e The effect of Ei-mix against anchorage-independent growth of K562 and 
SK-MEL-28 cell lines. Ei-mix 40 μM solution (4 μM of ten phytochemicals) was 
prepared and underwent serial dilution. Colony number was counted after 5 day-
incubation. One-way ANOVA *P < 0.05, **P < 0.01, ***P < 0.001 significant difference 
compared to the control group. 
 
  
Figure 4.5f The effect of Ei-mix against ERK2 signaling pathway. Ei-mix was treated to 
K562 and SK-MEL-28 cell lines at different concentrations for 15 min. 
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Figure 4.6 Simple depiction of a proposed mechanism of food-derived phytochemicals. 
A conventional anti-cancer mechanism using single phytochemical (left) was compared 
with the proposed mechanism where multiple phytochemicals with similar structure focus 
their effects on one protein (right). 
 
 
Table 4.1 Food sources of the naturally-occurring ERK inhibitors that constitute Ei-mix. 
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4.4 Discussion 
This work aimed to find a physiologically-relevant model that explains anti-
cancer effects of phytochemicals. Herein, we found that chemical similarity analysis of 
known ERK2 inhibitors led to determination of the crystal structure of ERK2 in complex 
with 5,7-DHC. Fisetin, quercetin, luteolin, 7,3’,4’-THIF and cyanidin were also identified 
as direct ERK2 inhibitors in vitro. Using 10 phytochemicals in mixture (Ei-mix), we 
proved that natural compounds at low doses can accumulatively inhibit ERK2. Ei-mix 
suppressed H-ras-induced cell transformation in NIH3T3 cells, and inhibited anchorage-
independent growth of K562 and SK-MEL-28 cells in where ERK2 is essential and 
highly expressed. Notably, western blots showed that phosphorylation of ERK2 
substrates were decreased by Ei-mix treatment. 
Fruits and vegetables are good sources of phytochemicals with health-promoting 
effects such as reducing cancer risks (258-259). Many basic researches revealing anti-
cancer effects of phytochemicals, especially ones elucidating target proteins of the small 
molecules, enhanced our understanding on molecular mechanisms (262). However, a 
limitation is that the health-promoting effect cannot be explained by a single 
phytochemical. In many cases, the physiological concentration of one phytochemical is 
too low to expect any effect, and this is a huge gap between basic research of 
phytochemicals and cohort studies. To tackle this issue, we hypothesized that similar 
phytochemicals may have a same target protein and the small molecules, although at low 
concentrations, can inhibit the target to where the effect is focused. Under in vitro 
condition, 10 different phytochemicals were able to accumulatively suppress ERK2 
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activity (Figure 4.4a). The Ei-mix worked as an ERK inhibitor by reducing 
phosphorylation of ERK2 substrates in cancer cells (Figure 4.5f). This new model 
(depicted in Figure 4.6) opens up possibilities that even phytochemicals with moderate or 
relatively weak activities can be used when combined with other molecules which have 
same target protein.  
Precision medicine refers to matching the right treatments with the individuals 
(4). Setting up prevention and treatment strategies often involves inhibition of genes and 
proteins that promote disease (4, 9). This new model using phytochemicals can be 
beneficial to who needs to inhibit Ras/Raf/MEK (mitogen-activated protein kinase 
kinase) pathway because ERK is their downstream protein. By increasing the 
consumption of food sources of Ei-mix (Table 4.1), one could boost up the concentration 
and thus degree of ERK inhibition. Although this new model still needs further 
evaluations, it will impact the cancer community by showing that many natural 
compounds can work together targeting ERK2, an important target in cancer. 
 
 
4.5 Experimental Procedures 
4.5.1 Cell culture, antibodies and reagents 
All cell lines were purchased from American Type Culture Collection (ATCC, 
Manassas, VA) and cytogenetically tested and authenticated before the cells were frozen. 
Cells are cultured in 10% FBS and antibiotic-containing RPMI (K562 and H1650), MEM 
(SK-MEL-28), MEM/F-12 (SH SY5Y). NIH3T3 was cultured in DMDM containing 10% 
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CS and antibiotics. Each vial of frozen cells was thawed and maintained for a maximum 
of 8 weeks (NIH3T3: 4 weeks). All antibodies were commercially available, including 
RSK2 and β-actin from Santa Cruz (Dallas, TX), pElk1 (S383), ERK2, pRSK 
(T359/S363), c-Myc, pERK1/2 (T202/Y204) and ERK1/2 from Cell Signaling 
Technology (Beverly, MA), p-c-Myc (S62) from Abcam (Cambridge, UK). Catechol, 
caffeic acid, fisetin, quercetin, luteolin and procyanidin B2 were purchased from Sigma-
Aldrich (St. Louis, MO). 5,7-DHC and cyanidin were purchased from ApexBio 
(Houston, TX). 7,3’,4’-THIF and CAY10561 were purchased from Cayman (Ann Arbor, 
MI). HOEC (266) and norathyriol (268) were synthesized as described earlier and were 
analyzed and authenticated by HPLC.  
 
4.5.2 ERK2/5,7-dihydroxychromone structure determination 
His-tagged recombinant human ERK2 was purified as described previously (ref). 
The crystals were produced by co-crystallization. Protein at 7.5 mg/ml was mixed with 
5,7-DHC 100mM stock solution in DMSO to achieve 1.5 mM of 5,7-DHC concentration 
and 1:9 protein/compound molar ratio. One or two microliters of protein:compound 
mixture were mixed with equal volume of precipitant comprised of 1.4M-1.5M 
ammonium sulfate, 2% PEG550, 0.1M HEPES, pH 7.5. The crystals grew slowly and 
were packed and tested after 1 month. The cryoprotectant solution comprised of 1.8M 
ammonium sulfate, 2% PEG550, 0.1M HEPES, pH 7.5 and 20% xylitol. 
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4.5.3 In vitro kinase assay 
The kinase assay was performed according to the instructions provided by 
Millipore. Briefly, ERK2 active kinase (100 ng) was incubated with compounds for 30 
min at 30°C. Then each reaction mixture was mixed with a relevantly respective 
substrate, isotope-unlabeled ATP and/or 10 μCi [γ-32P] ATP with each compound in 10 
μL of reaction buffer containing 20 mM HEPES (pH 7.4), 10 mM MgCl2, 10 mM MnCl2, 
and 1 mM dithiothreitol (DTT). After incubation at 30°C for 30 min, the reaction was 
stopped by adding 4 μL protein loading buffer and the mixture was separated by SDS-
PAGE. The 32P-labeled substrate was visualized by autoradiography. For the isotope-
unlabeled ATP kinase assay, p-Elk1 antibodies were visualized by Western blotting. 
 
4.5.4 Anchorage-independent cell growth assay 
Cells (8×103 per well) were suspended in basal medium eagle (BME) containing 
10% FBS and 0.3% agar and plated on solidified BME containing 10% FBS and 0.5% 
agar. After incubation for 5-10 days, the colonies were counted under a microscope using 
the Image-Pro Plus Software (v.6.1) program (Media Cybernetics, Rockville, MD).  
 
4.5.5 Foci formation assay 
Transformation of NIH3T3 cells was performing following standard protocols. 
Cells were transiently transfected with different concentrations of pcDNA3-H-RasG12V 
and pcDNA3-mock (as compensation to achieve equal amounts of DNA) plasmids and 
incubated overnight. Then the cells were cultured in 5% CS-DMEM with or without Ei-
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mix for 2 wk. The media were changed every other day. Foci were fixed and stained with 
0.5% crystal violet (220). 
 
4.5.6 Binding assay 
Compound-conjugated Sepharose 4B beads were prepared as described 
previously (265-266). A whole cell lysate was incubated with resveratrol-conjugated or 
control beads at 4°C overnight in NP-40 lysis buffer [50 mM Tris-HCl (pH 8.0), 150 mM 
NaCl, 1 mM EDTA, 0.5% NP-40 and protease inhibitor]. After washing 5 times with NP-
40 lysis buffer, the proteins bound to the beads were analyzed by Western blotting.  
 
4.5.7 Western blotting 
Cells were harvested and disrupted with NP-40 lysis buffer. The supernatant 
fraction was harvested after centrifugation at 13,000 rpm for 10 min. Protein 
concentration was determined by Bio-Rad protein assay reagent (Richmond, CA). Whole 
cell lysates were subjected to SDS-PAGE and transferred to a polyvinylidene difluoride 
membrane (Millipore, Billerica, MA). After blocking with 5% non-fat dry milk in 1 x 
TBS containing 0.05% Tween 20 (TBS-T), the membrane was incubated with a specific 
primary antibody, and then protein bands were visualized with the ECL system and 
LAS4000 Biomolecular Imager (GE Healthcare, UK) after hybridization with a 
horseradish peroxidase-conjugated secondary antibody.   
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4.5.8 Statistical analysis  
All quantitative results are expressed as mean values ± S.D. Statistically 
significant differences were obtained by one-way ANOVA. A p-value of < 0.05 was 
considered to be statistically significant. 
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Chapter 5: 
Recapitulation 
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 In Chapter 1, the work flow of precision oncology was categorized into two 
segments, precision diagnosis and precision therapy. We provided milestones and 
important aspects characterizing each segment. By reviewing targeted therapies clinically 
approved against breast cancer, lung cancer and melanoma, we revealed the current status 
and exposed possible challenges in precision oncology. Two of the most effective state-
of-the-art tools for the success of precision oncology were described.  
Throughout the next three chapters (Chapters 2, 3 and 4), we presented three 
examples of utilizing drugs and/or natural compounds for precision oncology: new drug 
candidate, drug-natural compound combination, and multiple compounds mixed at low 
doses. Newly synthesized small molecules can be developed as a direct inhibitor of 
important proteins (Chapter 2). Extracts from plants and their active compounds can 
reinforce the therapeutic effects of drugs (Chapter 3). Natural compounds from various 
food source can be mixed to suppress carcinogenesis (Chapter 4). 
Colorectal cancer is associated with aberrant activation of the Wnt pathway. β-
Catenin plays essential roles in the Wnt pathway by interacting with T-cell factor 4 
(TCF4) to transcribe oncogenes. We synthesized a small molecule, referred to as HI-B1, 
and evaluated signaling changes and biological consequences induced by the compound 
(Chapter 2). HI-B1 inhibited β-catenin/TCF4 luciferase activity and preferentially caused 
apoptosis of cancer cells which the survival is dependent on β-catenin. The formation of 
the β-catenin/TCF4 complex was disrupted by HI-B1 due to the direct interaction of HI-
B1 with β-catenin. Colon cancer patient-derived xenograft (PDX) studies showed that a 
tumor with higher levels of β-catenin expression was more sensitive to HI-B1 treatment 
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compared to a tumor with lower expression levels of β-catenin. The different sensitivities 
of PDX tumors to HI-B1 were dependent on the β-catenin expression level and 
potentially could be further exploited for biomarker development and therapeutic 
applications against colon cancer. 
Aspirin has received a considerable attention due to its anti-cancer effects on 
colon cancer patients with PIK3CA mutations. Ginger extract (GE) has protective effect 
against aspirin-induced hemorrhagic ulcer, and active components of GE possess anti-
colon cancer effects. This led us to investigate on the effects and mechanisms of aspirin 
and GE combination (Chapter 3). Co-treatment of aspirin and GE resulted in synergistic 
cytotoxicity in HCT116, DLD1 and HCT15 colon cancer cell lines. The combination 
treatment caused apoptosis by enhancing p53 and p21 protein expressions. 6-Shogaol was 
identified as an active component of GE showing inhibition of anchorage-independent 
growth and direct binding with Akt1/2. In colon cancer patient-derived xenograft (PDX) 
models, co-treatment of aspirin 100 mg/kg plus GE 5 mg/kg significantly suppressed 
tumor growth. Of note, tumor-suppressive effects were similar between the combination 
group and aspirin 400 mg/kg group, but weight loss was shown only in aspirin-only 
group. The combination of aspirin and GE could be further exploited for therapeutic 
applications against colon cancer. 
Fruits and vegetables are good sources of phytochemicals that possess health-
promoting effects such as reducing the risk of cancer. Although the anti-cancer effects of 
phytochemicals are heavily investigated, there exists a limitation that a single 
phytochemical is not correlated with reducing risks of cancer. This is partly due to the 
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low concentration of each phytochemical in our body. To tackle this issue, we 
hypothesized that many phytochemicals with similar chemical structure may have a same 
target protein and the natural compounds, although at low doses, can inhibit the activity 
of the protein to where the anti-cancerr effects are focused (Chapter 4). From chemical 
similarity analysis of four known ERK inhibitors, we found six new ERK2 inhibitors 
with similar chemical structures. The ten phytochemicals were able to accumulatively 
inhibit ERK2 activity in vitro. ERK inhibitor mixture that each phytochemical exists at a 
low concentration suppressed H-ras-induced cell transformation of fibroblast, and 
inhibited anchorage-independent growth of cancer cells in where ERK2 is essential and 
highly expressed. This work will impact the cancer community by showing that many 
natural compounds can work together targeting ERK2, an important target in cancer.  
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Appendix 
Precision medicine: the foundation of future cancer therapeutics 
(This commentary is published in npj Precision Oncology, (2017) 1:12; 
doi:10.1038/s41698-017-0016-z) 
 
Based on early evidence of fossilized bone tumors that were found in ancient 
Egyptian mummies, cancer is an ancient disease (279). The term “carcinoma” to refer to 
cancer was first used around 400 BC by Hippocrates (280). The understanding of cancer 
mechanisms began when John Bennett and Rudolf Virchow observed the abnormal 
accumulation of white blood cells in patients in 1845, which was one of the first cancers 
detected by microscopy (281). In contrast to the long history of the disease, diagnosis and 
treatment of cancer at a cellular or molecular level is a relatively new strategy. Although 
the field of oncology has developed and expanded dramatically, a single drug has not yet 
been discovered that can cure all patients, even those with similar cancer types. We now 
know that cancer is an extremely heterogeneous disease, which explains differences not 
only between cancer cells from different patients, but also differences between cancer 
cells within a single patient (282). Clearly, more effective strategies are critically needed 
to defeat the long-standing enemy known as cancer. 
The concept and practice of precision medicine is a methodical and systematic 
movement aimed at defeating diseases such as cancer (4). Cancer is a major focus of the 
precision medicine initiative and developments in precise and effective treatments could 
benefit many other chronic diseases. Precision oncology or precision medicine of cancer 
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focuses on matching the most accurate and effective treatment to each individual cancer 
patient based on the genetic profile of the cancer and the individual. Because every single 
cancer patient exhibits a different genetic profile and the profile can change over time, 
more patients will benefit if therapeutic options can be tailored to that individual, thus 
avoiding the idea that “one-size-fits-all” in terms of cancer treatment. 
Results of one randomized clinical trial and a small number of feasibility and/or 
tumor response studies (25, 283-286) focusing on the concept of precision medicine have 
had limited success(287). Naturally, opponents of precision medicine have criticized the 
strategy based on the results of the small number of clinical studies (160, 163). However, 
concluding that precision medicine will not work is premature because the precision 
medicine approach has not yet been fully tested in a sufficient number of trials. In 
addition, the suggestion has been made that having inadequate access to specific 
therapeutic agents and an insufficient number of tumor samples may have contributed to 
the limited success (163). Because cancer is a highly heterogeneous disease both between 
patients and within the same patient, the ability to cope with changes in the clinical trial 
setting is extremely challenging. Many creative and bold ideas of precision medicine 
have not yet made the transition from the lab bench to the clinic and need to be more 
fully evaluated in small clinical studies. For example, the microbiota is now recognized 
as a key player in health (288). The microbiota influences endocrinology and disease 
status and alters drug response and resistance, and this could hold true for cancer and the 
efficiency of cancer treatments. Sequencing the human microbiome and modulating the 
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host-microbiota interactions in individual patients may be one approach to improve 
therapeutic outcomes (288-289). 
Questions that must be addressed include whether precision oncology is just a 
theory or whether it realistically assures a better future and if truly promising, how can 
the application of precision oncology be improved and effectively implemented into the 
clinic? Several lines of evidence strongly support the idea that precision oncology could 
likely benefit more patients compared to traditional chemotherapies. First, some patients’ 
lives have already been substantially improved by target-based therapies compared to 
conventional cytotoxic therapies. One of the most notable examples is the discovery of 
the Bcr-Abl gene fusion in chronic myeloid leukemia (CML). Uncovering this genetic 
driver of CML lead to the development of a selective inhibitor of BCR-ABL, imatinib, 
which exhibited broader treatment coverage because, unlike other gene mutations, the 
Bcr-Abl gene fusion occurs in almost all CML patients. This compound improved the 
overall survival rates of CML patients to 90% over 5 years and 88% over 8 years (290). 
Another example includes the effectiveness of drugs like trastuzumab, lapatinib, 
pertuzumab or ado-trastuzumab emtansine against human epidermal growth factor 
receptor 2 (HER2)-positive breast cancer. Compared to chemotherapy alone, the addition 
of trastuzumab to chemotherapy significantly slowed the disease progression (i.e., 
median, 4.6 vs. 7.4 months), increased the objective response rate (i.e., 32 vs. 50%), 
prolonged survival time (i.e., median, 20.3 vs. 25.1 months) and reduced the risk of death 
by 20% (57). Lapatinib plus chemotherapy (i.e., capecitabine) achieved a longer median 
time to disease progression compared to chemotherapy alone (i.e., 8.4 vs. 4.4 months) 
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(291). A combination of pertuzumab, trastuzumab, and chemotherapy (i.e., docetaxel) 
further improved the median overall survival time to 56.5 months compared with a 
combination of only trastuzumab and chemotherapy (i.e., 40.8 months) (58). Treatment 
with ado-trastuzumab emtansine, a conjugate of a HER2 monoclonal antibody and a 
cytoxic drug, significantly improved the length of progression-free survival and overall 
survival with lower adverse effects when compared with lapatinib and chemotherapy 
(i.e., capecitabine) (59). These two excamples demonstrate how the identification of key 
mutations like the Bcr-Abl fusion or HER2 can clearly benefit a larger number of select 
cancer patients. 
Second, many strategies are now available to identify important molecular targets 
for therapeutic intervention. Synthetic lethality is one unique strategy directed toward 
identifying cancer vulnerabilities (292). This strategy is based on the discovery that cell 
death is caused by a combination of deficiencies in the expression of two or more genes, 
whereas deficiency in only one of these genes can increase viability (292-293). In 2005, 
the BRCA and poly ADP ribose polymerase (PARP) genes were found to have a synthetic 
lethal relationship (294-295). In 2014, the FDA (Food and Drug Administration) 
authorized accelerated approval of olaparib, a PARP inhibitor, to treat BRCA-mutant 
ovarian cancer patients (296-299). Progression free survival of BRCA-mutant ovarian 
cancer patients was significantly prolonged by olaparib compared to the placebo 
treatment (i.e., median, 11.2 vs. 4.3 months) (299). Likewise, several candidate proteins 
were identified to treat cancers that over-express Myc, a transcription factor for which 
small-molecule inhibitors are currently unavailable (300-304). Within just a 5-year 
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timespan, researchers found that Myc-amplified tumors were sensitive to CDK1, aurora 
kinase B, and BRD4 inhibition (300-301). Although many of these inhibitors have yet to 
translate into clinical successes, Phase I trials of three BRD4 inhibitors are ongoing (CPI-
0610 and TEN-010) or have just finished (OTX015) (305-306). These findings suggest 
that changes in gene A in cancer does not necessarily mean that gene A is the best target 
but instead, targeting its synthetic lethal partner might be a more effective strategy. 
Third, clinical trial design is constantly evolving to overtake tumor heterogeneity 
from patient to patient. The Molecular Analysis for Therapy Choice (NCI-MATCH) is a 
clinical trial selecting treatments based on genetic features of patients, not traditional 
tumor histology (165). The cancer patients will be assigned to 1 of 25 different treatment 
arms based on their genetic mutation profile. The overall response rate will be the 
endpoint to measure success. However, no control arms will be included, which could 
dramatically affect the interpretation of the final results. Even though a number of 
questions have been raised, the investigators are very optimistic that the results will 
further the efforts to implement precision oncology treatments. The Molecular Profiling-
based Assignment of Cancer Therapy (NCI-MPACT) is another innovative clinical trial 
to test the hypothesis that targeting an oncogenic driver mutation is more efficacious than 
not targeting it. NCI-MPACT will recruit advanced cancer patients who have been 
unresponsive to standard therapeutic options and possess mutations in one of three 
genetic pathways that include DNA repair, PI3-K/mTOR (phosphoinositide-3 
kinase/mammalian target of rapamycin) and Ras/Raf/MEK (mitogen-activated protein 
kinase kinase). Patients without a driver mutation will not be eligible for further treatment 
  170 
(307). Although this trial is similar to the NCI-MATCH in that patients will undergo 
tumor biopsies when enrolled, patients in the NCI-MPACT study will be assigned to one 
of two arms:  treatment with drug(s) designed to target the mutation or treatment with 
drug(s) not prospectively identified to target the mutation. By evaluating gene targets 
across the histologic subtypes with NCI-MATCH and addressing the importance of 
driver mutations with NCI-MPACT trials, the efficacy of diagnosis and therapies could 
be significantly enhanced. 
Finally, the influence of new technologies such as the CRISPR/Cas system and 
cryo-electron microscopy (cryo-EM) will broaden and sharpen our ability to identify 
novel therapeutic targets for precision oncology. CRISPR/Cas technology  enables 
controlled exchange, insertion and deletion of DNA sequences unlike spontaneous 
mutation and can easily generate animal models that mimic mutations status of patients 
(308). Recently, a gene therapy trial to treat myeloma, melanoma and sarcoma with 
CRISPR/Cas has been approved by the National Institute of Health (NIH) and is awaiting 
approval from the FDA (309). In addition to CRISPR/Cas, cryo-EM is a promising tool 
for precision oncology. Cryo-EM is a type of transmission EM in which samples are 
examined at cryogenic temperatures (310). Because the samples (e.g., proteins and 
viruses) are frozen in their native states, researchers can study biological events 
accurately at the subatomic or atomic level. For an instance, a 2.3 Å resolution cryo-EM 
structure of p97 showed a large corkscrew-like hexameric form, revealed its interactions 
with an allosteric inhibitor and displayed conformational changes induced by adenosine 
tri-phosphate (ATP) (311). Visualization of intact proteins and anti-cancer drugs at 
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subatomic or atomic levels will assist researchers in understanding the consequences of 
genetic alterations on drug response and resistance. 
In spite of some early setbacks, precision oncology still has a great deal of 
promise and should not be abandoned hastily. The challenge of tumor heterogeneity 
should not discourage or intimidate efforts to overcome cancer but should push the field 
forward. As practice makes perfect, precision mends patients. 
 
